Introduction {#s1}
============

Senescence is defined as irreversible arrest of cell growth and loss of replicative capacity ([@bib27]). Senescent cells have a large, flattened morphology and a characteristic secretory phenotype. They may be multinucleate, exhibit nuclear distortion, and contain senescence-associated heterochromatin foci (SAHFs) ([@bib41]). Senescence can be induced by various stimuli such as DNA damage, metabolic or oxidative stress, or expression of oncoproteins ([@bib44]; [@bib42]; [@bib12]).

The p16/retinoblastoma protein (RB) and p53 tumor suppressor pathways are key regulators of senescence induction and maintenance in many cell types ([@bib53]). p14^ARF^-p53 activates p21, whereas the p16^INK4a^-RB pathway culminates in E2F transcriptional target repression and senescence ([@bib15]). Expression of *CDKN2A-p14*^*ARF*^ and *CDKN1A*-*p21*^*CIP*^ is repressed by the related transcription factors TBX2 and TBX3; this is the postulated mechanism for senescence bypass of *Bmi1*−/− and SV40 transformed mouse embryonic fibroblasts by overexpressed TBX2 and TBX3, respectively ([@bib38]; [@bib8]; [@bib56]).

Mutations in human *TBX3* cause a constellation of severe birth defects called ulnar-mammary syndrome ([@bib3]). Efforts to understand the molecular biogenesis of this developmental disorder uncovered additional functions for TBX3 beyond transcriptional repression ([@bib20]; [@bib24]; [@bib43]) as well as critical roles in adult tissue homeostasis ([@bib23]). The pleiotropic effects of TBX3 gain and loss of function suggest its molecular activities are context and cofactor dependent.

Despite the biologic importance of TBX3, few interacting proteins or target genes have been discovered, and the mechanisms underlying its regulation of cell fate, cell cycle, and carcinogenesis are obscure. We found that TBX3 associates with CAPERα ([C]{.ul}oactivator of [AP]{.ul}1 and [E]{.ul}strogen [R]{.ul}eceptor), a protein identified in a liver cirrhosis patient who developed hepatocellular carcinoma ([@bib36]). CAPERα regulates hormone responsive expression and alternative splicing of minigene reporters in vitro ([@bib40]; [@bib17]) but its in vivo functions are unknown.

We show that a CAPERα/TBX3 repressor complex is required to prevent premature senescence of primary cells and regulates the activity of core senescence pathways in mouse embryos. We discovered co-regulated targets of this complex in vivo and during oncogene-induced senescence (OIS), including a novel tumor suppressor*,* the lncRNA *UCA1*. *UCA1* is sufficient to induce senescence and does so in part by sequestering hnRNP A1 to specifically stabilize *CDKN2A-p16*^*INK*^ mRNA. Our finding that CAPERα/TBX3 regulates p16 levels by dual, reinforcing mechanisms position CAPERα/TBX3 and *UCA1* upstream of multiple members of the p16/RB pathway in the regulatory hierarchy that controls cell proliferation, fate and senescence.

Results {#s2}
=======

CAPERα interacts with TBX3 in vivo {#s2-1}
----------------------------------

We recently discovered that TBX3 (human) and Tbx3 (mouse) interact with RNA-binding and splicing factors ([@bib43]). Among these, mass spectrometry of anti-TBX3 immunoprecipitated (IP\'d) proteins identified CAPERα ([Figure 1A](#fig1){ref-type="fig"}). Since TBX3 functions in mammary development and may contribute to the pathogenesis of breast and other hormone responsive cancers ([@bib16]), its interaction with an ERα co-activator drove further investigation.10.7554/eLife.02805.003Figure 1.CAPERα and TBX3 directly interact via the TBX3 repressor domain.(**A**) Representative spectrum for CAPERα identified in anti-TBX3 co-IP of HEK293 cell lysates. Mass spec analysis identified six specific CAPERα peptides, providing 8.5% sequence coverage of the protein. This spectrum shows fragmentation of one of these peptides, C\*PSIAAAIAAVNALHGR, with diagnostic b- and y-series ions shown in red and blue, respectively. \* indicates carbamidomethylation. (**B**) Anti-CAPERα immunoblot (IB) analysis of anti-CAPERα immunoprecipitated (IP\'d, lane 2) e10.5 mouse embryo lysates. Black arrowheads indicate IgG heavy chain and red indicate protein of interest (CAPERα or TBX3). (**C**) Anti-Tbx3 IB of anti-Tbx3 (lane 4) and anti-Caperα (lane 5) IP\'d mouse embryo lysates. Rabbit (r)-IgG (lanes1, 6) and mouse (m)-IgG (lane 7) are negative controls. (**D**) In vitro MBP pull down assay: MBP and MBP-Tbx3 bound amylose affinity columns were incubated with GST or GST-CAPERα. Bound proteins were eluted, subjected to SDS-PAGE followed by IB with anti-CAPERα antibody. (**E**--**G**) Colocalization of Tbx3 and Caperα in vivo shown by immunohistochemical analysis of sectioned e10.5 mouse embryo: embryonic dorsal root ganglion (DRG, **E**), proximal (**F**), and distal (**G**) limb bud with anti-Tbx3 (red) and anti-Caperα (green) antibodies and DAPI (blue). White arrowheads in **G** label representative ectodermal and mesenchymal cells with cytoplasmic Tbx3 and nuclear Caperα. (**H**) Schematic representation of mouse Tbx3 overexpression constructs.Tbx3 DNA binding domain (DBD) point, ΔRD and exon7 missense proteins are untagged and the C-terminal deletion mutants are Myc-tagged. (**I**) Anti-TBX3 IB of HEK293 cell lysates transfected with control or anti-TBX3 shRNA. (**J**) Anti-CAPERα IB of anti-CAPERα IP\'d samples from HEK293 cells transfected with anti-TBX3 shRNA and expressing mouse Tbx3 proteins listed at top. Production and IP of endogenous CAPERα is not affected by production of mutant Tbx3 proteins. (**J′**) Anti-Tbx3 IB of anti-CAPERα IP\'d samples from HEK293 cells transfected with anti-TBX3 shRNA and expressing Tbx3 proteins as in **J**. The DBD point mutant proteins (lanes 2, 3) interact with CAPERα as efficiently as wild type Tbx3 (lanes 1, 4). (**K**) Anti-Myc IB of anti-Myc IP\'d samples from HEK293 cell lysates expressing Myc-tagged mouse Tbx3 C-terminal deletion mutants. The mutant proteins are expressed and efficiently IP\'d. These cells were not treated with anti-TBX3 shRNA because the expression constructs produce a Myc- tagged mutants that can be IP\'d independently of endogenous TBX3. (**K′**) anti-CAPERα IB of anti-Myc IP\'d samples from HEK293 cell lysates expressing Myc-tagged mouse Tbx3 C-terminal deletion mutants. These cells were not treated with anti-TBX3 shRNA because the expression constructs produce a Myc- tagged mutants that can be IP\'d independently of endogenous TBX3. (**L**) Anti-Tbx3 IB of anti-Tbx3 IP\'d samples from HEK293 cells transfected with anti-TBX3 shRNA and expressing wt or repressor domain deletion mutant (ΔRD) mouseTbx3. The shRNA does not prevent production of the overexpression proteins. (**L′**) Anti-CAPERα IB of HEK293 cells transfected with anti-TBX3 shRNA and expressing mouse wt or ΔRD Tbx3 proteins and IP\'d with anti-Tbx3 or IgG. Loss of the repressor domain prevents interaction with CAPERα. Black arrowheads indicate IgG heavy chain and red indicate protein of interest (CAPERα or TBX3). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.003](10.7554/eLife.02805.003)10.7554/eLife.02805.004Figure 1---figure supplement 1.Missense mutation of the C-terminus of Tbx3 disrupts interaction with CAPERα.(**A**) Anti-Tbx3 IB of exon 7 missense (ex7) and wt proteins expressed in HEK293 cells also transfected with anti-TBX3 shRNA. The overexpressed proteins are produced (red arrowhead). (**B**) anti-CAPERα and anti-TBX3 (**C**) IB of anti-CAPERα and negative control IP\'d samples from HEK293 cells transfected with anti-TBX3 shRNA and overexpressing ex7 missense or wt Tbx3. Production and IP of endogenous CAPERα is not affected by production of mutant Tbx3 proteins. (**C**) Anti-Tbx3 IB of anti-CAPERα and negative control IP\'d samples from HEK293 cells transfected with anti-TBX3 shRNA and overexpressing ex7 missense or wt Tbx3. The missense mutation disrupts interaction between Tbx3 and CAPERα. Black arrowheads indicate IgG heavy chain and red indicate protein of interest (CAPERα or TBX3). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.004](10.7554/eLife.02805.004)

To determine if Tbx3 and Caperα interact in vivo, we IP\'d endogenous Caperα from embryonic day (e)10.5 mouse embryo lysates ([Figure 1B](#fig1){ref-type="fig"}). Immunoblotting for Tbx3 confirmed its interaction with Caperα ([Figure 1C](#fig1){ref-type="fig"}, lane 5) and in vitro pull down assays revealed that their interaction is direct ([Figure 1D](#fig1){ref-type="fig"}, lane 6). *Caperα* is very broadly expressed during mouse embryonic development (Moon, unpublished), whereas *Tbx3* expression is very tissue specific and dynamic. We thus questioned whether the endogenous proteins interact in mouse tissues relevant to malformations seen in humans with UMS. Immunohistochemistry on sectioned e10.5 embryos showed that Tbx3 and Caperα proteins are co-expressed and have distinct localization patterns in different tissues: Caperα is detected in all dorsal root ganglia nuclei ([Figure 1E](#fig1){ref-type="fig"}), some of which contain co-localized Tbx3; in proximal limb mesenchyme, Tbx3 and Caperα co-localize in nuclei ([Figure 1F](#fig1){ref-type="fig"}) while in some distal cells and the ectoderm, Caperα is nuclear and Tbx3 is cytoplasmic ([Figure 1G](#fig1){ref-type="fig"}, white arrowheads). Such tissue specificity suggests that functions of the Caperα/Tbx3 complex are context dependent.

TBX3 DNA binding and repressor domains (DBD, RD) independently mediate interactions with partner proteins ([@bib9]; [@bib11]; [@bib43]). To identify domains required for CAPERα interaction, we used a series of overexpression plasmids encoding mouse Tbx3 proteins with different mutations and functional domains ([Figure 1H](#fig1){ref-type="fig"}). The DBD, deleted repressor domain (ΔRD) and exon7 missense mutants are untagged proteins, whereas the C-terminal deletion mutants are Myc-tagged.

To assay the interactions of the untagged exogenous proteins with endogenous CAPERα in HEK293 cells, we needed to knockdown endogenous TBX3 with shRNA ([Figure 1I](#fig1){ref-type="fig"}). We previously demonstrated that mutant Tbx3 proteins produced from the overexpression plasmids are present in *TBX3* knockdown HEK293 cells (Figure 2 in [@bib43]). CAPERα is present and can be IP\'d in the context of knockdown of endogenous *TBX3* and subsequent overexpression of mutant mouse Tbx3 proteins ([Figure 1J](#fig1){ref-type="fig"}). Immunoblot of anti-CAPERα IP\'d samples shows that the endogenous CAPERα interacts with Tbx3 DBD mutant proteins ([Figure 1J′](#fig1){ref-type="fig"}, lanes 2 and 3 are L143P and N227D, respectively).

The Tbx3 deletion constructs encode Myc- tagged mutants that can be distinguished from endogenous TBX3, so interactions were assayed in wild-type HEK293 cells. Myc-tagged deletion mutants are IP\'d by the anti-Myc antibody ([Figure 1K](#fig1){ref-type="fig"}), and probing anti-Myc IP\'d material for CAPERα reveals that deletions more proximal than amino acid 655 disrupt the CAPERα/Tbx3 interaction ([Figure 1K′](#fig1){ref-type="fig"}).

The observation that deletions of the Tbx3 C-terminus disrupt the CAPERα/Tbx3 interaction led us to test whether the C-terminal repressor domain, which is crucial for the ability of Tbx3 to function as a transcriptional repressor and immortalize fibroblasts ([@bib9]), plays a role. Although the untagged ΔRD mutant is produced in TBX3 shRNA knockdown cells and IP\'d by the anti-Tbx3 antibody ([Figure 1L](#fig1){ref-type="fig"} and [@bib43]) it does not interact with CAPERα ([Figure 1L′](#fig1){ref-type="fig"}). CAPERα also fails to interact with a C-terminal Tbx3 frameshift mutant similar to one identified in humans with UMS ([@bib4]) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

CAPERα and TBX3 are required to prevent premature senescence of primary human and mouse cells {#s2-2}
---------------------------------------------------------------------------------------------

Roles for TBX3 in cell cycle regulation and senescence of primary cells have not been reported. We employed loss-of-function to test whether TBX3 is required for sustained proliferation of primary cultured human foreskin fibroblasts (HFFs) and to determine if CAPERα functions in this process. We tested two different CAPERα and TBX3 shRNAs (please see 'Materials and methods' for sequences and location in target mRNAs). Both CAPERα and TBX3 shRNAs effectively decreased the amount of CAPERα mRNA ([Figure 2---figure supplements 1A and 2A,B](#fig2s1 fig2s2){ref-type="fig"}). Knockdown of either protein resulted in a dramatic increase in senescence associated β-galatosidase activity (SA-βgal, [Figure 2A--D](#fig2){ref-type="fig"}; [Figure 2---figure supplements 1 and 2C--H](#fig2s1 fig2s2){ref-type="fig"}). This effect is specific because it occurs with two different shRNAs and is rescued by overexpression of CAPER*α* ([Figure 2---figure supplement 1B,E,G,H](#fig2s1){ref-type="fig"}) and Tbx3 ([Figure2---figure supplement 2B,E,G,H](#fig2s2){ref-type="fig"}). For all subsequent experiments, CAPER*α* shRNA \'A\' and TBX3 shRNA \'A\' were used to perform knockdown (KD) in HFFs (protein knockdowns are shown in [Figure 2---figure supplements 1 and 2](#fig2s1 fig2s2){ref-type="fig"}, I panels).10.7554/eLife.02805.005Figure 2.Knockdown of endogenous *CAPERα* and *TBX3* in primary human fibroblasts and mouse embryos induces premature senescence and disrupts expression of cell cycle and senescence regulators.(**A**--**C**) Representative bright field images of senescence associated β-galactosidase (SA-βG) assays of HFFs transduced with control, *TBX3* shRNA A or CAPERα shRNA A. Only occasional cells in the control transduction have detectable lacZ staining (blue) whereas knockdown of either TBX3 or CAPERα results in marked changes in cell morphology and increased lacZ staining. (**D**) Bar graph quantitating % beta-galactosidase positive cells from four replicate plates of SA-βgal assays. \* indicates p\<0.001 compared to control. (**E** and **F**) 3T5 cell proliferation assay ([@bib45]) of cumulative population doublings in HFFs transduced at passage 30 with control, TBX3 or CAPERα shRNAs. These are representative curves of duplicate experiments; each point on the curve is a measurement of cell count from a single plating followed over the course of the experiment as described in methods. (**G**--**J**) Immunohistochemical analysis of H3K9me3 immunoreactivity (red) and DAPI (blue) in HFFs after knockdown with control (**G** and **I**), TBX3 (**H**), or *CAPERα* (**J**) shRNAs. Individual channels are shown and the merged image is on the right. Note increased nuclear punctate staining consistent with Senescence-associated heterochromatin foci (SAHFs) in both channels and evidence of nuclear disruption (white arrowheads in red channel) after loss of either TBX3 or *CAPERα*. (**K**--**M**) Analysis of cell cycle and senescence marker transcript levels in HFFs transduced with control, *TBX3,* or *CAPERα* shRNAs. (**K**) Relative transcript levels assessed by quantitative real time-PCR (qPCR) of cDNA. Values reflect fold change in knockdown HFFs relative to control after normalization to *HPRT* levels. Note general pattern of expression changes are similar in TBX3 (blue) and CAPERα (red) knockdowns. Data are plotted as fold change mean ± standard deviation. \* indicates p\<0.05 relative to control. (**L** and **M**) Agarose gel of PCR amplicons of cDNAs reverse transcribed from TBX3 (**L**) or CAPERα (**M**) shRNA knockdown HFF RNA reveals similar decreases in cell cycle promoting genes CDK2 and 4 in TBX3 and CAPERα knockdowns and increased p21 levels. (**N** and **O**) SA-βgal assay of wild type and *Tbx3* null MEFS reveals that Tbx3 is required to prevent premature senescence of primary murine embryonic fibroblasts (MEFs). (**P**) Quantitation of % beta-galactosidase positive cells from five replicate experiments exemplified in O, P. \* indicates p\<0.01. (**Q**) 3T5 cell proliferation assay of cumulative population doublings in wild-type and *Tbx3* null MEFs. These are representative curves from duplicate experiments; each point on the curve is a measurement of cell count from a single plating followed over the course of the experiment as described in \'Materials and methods\'. (**R**) IBs to assay levels of cell cycle and senescence proteins in wild type and *Tbx3* null embryo lysates. Tubulin loading control is at top left (Tub). The changes at the protein level correlate with those observed at the RNA level (**K**--**M**) and RB is hypophosphorylated on multiple serine residues consistent with increased p16 and decreased CDK activity. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.005](10.7554/eLife.02805.005)10.7554/eLife.02805.006Figure 2---figure supplement 1.Effective knockdown of endogenous CAPER**α** in primary human foreskin fibroblasts using viral shRNA transduction.(**A**) RT-PCR analysis of *CAPERα* and *HPRT* transcript levels in HFFs transduced with two different retroviruses producing anti-CAPERα shRNAs (CAP sh A and B) and control shRNA virus (Ctl sh). Red arrowhead indicates CAPERα-specific amplicon. (**B**) RT-PCR analysis of *CAPERα* and *HPRT* transcript levels in HFFs transduced with retroviruses producing anti-CAPERα shRNA A and a *CAPERα* overexpression virus (CAP OE). Note rescue of *CAPERα* expression by overexpression virus. (**C**--**G**) SA-βGal assays of HFFs transduced with control or CAPERα shRNAs A or B and rescue by CAPERα overexpression. (**H**) Quantitation of SA-βGal assays in **C**--**G**. \* indicates p\<0.01 compared to control shRNA. (**I**) Western blot showing depletion of endogenous CAPER*α* protein by CAP shRNA A. Anti-tubulin IB is loading control. This CAPER*α* shRNA 'A' was used for all subsequent CAPER*α* shRNA knockdown experiments. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.006](10.7554/eLife.02805.006)10.7554/eLife.02805.007Figure 2---figure supplement 2.Effective knockdown of endogenous TBX3 in primary human foreskin fibroblasts using viral shRNA transduction.(**A**) RT-PCR analysis of *TBX3* and *HPRT* transcript levels in primary human foreskin fibroblasts (HFFs) transduced with control (Ctl sh) or *TBX3* (TBX3 shA) shRNA retrovirus. (**B**) RT-PCR analysis of *TBX3* and *HPRT* transcript levels in primary human foreskin fibroblasts (HFFs) transduced with control (Ctl sh) or *TBX3* (TBX3 shB) shRNA retrovirus. (**C**--**G**) SA-βGal assays of HFFs transduced with control or TBX3 shRNAs A or B and rescue by Tbx3 overexpression. (**H**) Quantitation of SA-βGal assays in **C**--**G**. \* indicates p\<0.01 compared to control shRNA. (**I**) Western blot showing depletion of endogenous TBX3 protein by TBX3 shRNA A. Anti-tubulin IB is loading control. This TBX3 shRNA 'A' was used for all subsequent TBX3 shRNA knockdown experiments. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.007](10.7554/eLife.02805.007)10.7554/eLife.02805.008Figure 2---figure supplement 3.*Tbx3* null murine embryonic fibroblasts (MEFS) have altered lamin **β**1 localization, nuclear disruption and mislocalized Caper*α*.. (**A**--**B′**) Representative WT and *Tbx3* null MEFs cells stained for laminβ1 at passage (P) 4 (**A** and **B**) and P1 (**A′** and **B′**); note nuclear distortion and rupture in senescing *Tbx3* null MEFs as early as P1. (**C**) Quantitation of % distorted nuclei in WT vs *Tbx3* null MEFs. \* indicates p\<0.05. (**D**--**F′**) Immunohistochemistry for Caperα (green) and DNA (DAPI, blue) in control and *Tbx3* null MEFs at P1 (**D** and **D′**) and P2 (**E**--**F′**). In mutant cells, Caperα signal shifts to nucleus from cytoplasm at P1, and large intranuclear Caperα+ foci are present by P2. (**G**) qPCR quantitation of senescence marker genes in WT vs *Tbx3* null MEFs. Data are displayed as mean fold change ± standard deviation relative to WT after normalization to HPRT levels. \* indicates p\<0.01. \# indicates p\<0.05. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.008](10.7554/eLife.02805.008)

The effects of CAPERα and TBX3 KD on HFF cell growth, and SA-βgal activity suggest induction of premature senescence. Consistent with this, both KDs dramatically influenced nuclear structure, chromatin organization and formation of SAHFs ([Figure 2G--J](#fig2){ref-type="fig"}). Expression of senescence mediators was increased and conversely, expression of cell growth and cell cycle promoting genes was similarly decreased by CAPERα and TBX3 KD ([Figure 2K--M](#fig2){ref-type="fig"}). Increased expression of *CDKN2A-p16*^*INK*^ (henceforth referred to as *p16*^*INK*^) and decreased *PCNA, E2F1* and *2, CDK2, CDK4, CDC2* transcripts indicate that CAPERα/TBX3 represses the p16/RB pathway in proliferating HFFs. *PMAIP1, CDKN1A-p21,* and other p53 pathway members were also increased. Collectively, these data indicate that CAPER*α* and TBX3 are required to prevent senescence of primary HFFs and act upstream of major cell cycle and senescence regulatory pathways.

*Tbx3* null murine embryonic fibroblasts undergo p16/RB-mediated premature senescence, Caper*α* mislocalization and nuclear disruption {#s2-3}
--------------------------------------------------------------------------------------------------------------------------------------

Tbx3 deficiency in mice causes lethal embryonic arrhythmias and limb defects however, these phenotypes are not due to increased apoptosis ([@bib23] and Emechebe and Moon, unpublished). We hypothesized that Tbx3 may prevent senescence of embryonic cells, and so examined murine embryonic fibroblasts (MEFs) from e13.5 wild type (WT) and *Tbx3* null (−/−) embryos. WT MEFs undergo ∼10 passages with regular, 20 hr doubling times. In contrast, *Tbx3−/−* MEFs had increased SA-βgal activity and ceased proliferating after only four passages ([Figure 2N--Q](#fig2){ref-type="fig"}). Most *Tbx3−/−* MEFs had distorted or ruptured nuclei ([Figure 2---figure supplement 3A--C](#fig2s3){ref-type="fig"}) and laminβ1 staining was already altered at passage 1 ([Figure 2---figure supplement 3B′](#fig2s3){ref-type="fig"}). *Caperα* null mutant embryos do not survive long enough to generate MEFs for complementary experiments (Emechebe and Moon, unpublished) however, Caperα localization is markedly abnormal in *Tbx3−/−* MEFS after only 1 passage ([Figure 2---figure supplement 3D--F′](#fig2s3){ref-type="fig"}). These data suggest that Tbx3 is required for preservation of nuclear architecture and to tether Caperα in its normal nuclear domains in proliferating cells.

Consistent with premature senescence seen in *Tbx3*−/− MEFs, key pro-senescence pathways are activated after loss of Tbx3 in vivo: in protein lysates from *Tbx3−/−* embryos, RB was hypophosphorylated on multiple serine residues, consistent with increased p16 and decreased Cdk2 and Cdk4 protein levels relative to control ([Figure 2R](#fig2){ref-type="fig"}). The levels of p21 and other senescence markers were increased, while numerous Cyclins and other Cdks were decreased ([Figure 2R](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3G](#fig2s3){ref-type="fig"}). All of these findings are consistent with a requirement for Tbx3 to prevent senescence in embryonic mice and MEFs.

Previous studies have suggested that overexpression of TBX3 permits senescence bypass by directly repressing *CDKN2A-p14*^*ARF*^ (*p14*^*ARF*^) to activate p53 ([@bib8]), but a role for TBX3 in regulating *p16*^*INK*^ and the RB pathway has not been demonstrated. Thus, we expected that loss of p53 would rescue senescence resulting from TBX3 or CAPER*α* KD. To test this, we transduced TBX3 and CAPER*α* KD HFFs with shRNA to p53 ([@bib50]) and assayed SA-βgal activity and growth. Surprisingly, although p53 shRNA effectively decreased p53 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), it did not rescue SA-βgal activity or growth arrest due to absence of TBX3 or CAPER*α* ([Figure 3B,E,G,H](#fig3){ref-type="fig"}). In contrast, shRNA-mediated KD of either RB ([@bib7]) or p16 ([@bib25]) ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}) rescued these phenotypes in TBX3 and CAPER*α* KD cells ([Figure 3C,F--H,I--N](#fig3){ref-type="fig"}). These rescue experiments demonstrate that the p16/RB pathway mediates senescence downstream of CAPER*α* and TBX3 loss-of-function in primary cells.10.7554/eLife.02805.009Figure 3.RB and p16 mediate senescence after CAPERα/TBX3 loss of function and CAPERα/TBX3 regulates chromatin structure of *CDKN2A-p16*.(**A**--**F**) SA-βgal assays of HFFs stably transduced with control (Ctl) or p53 ([@bib50]) or RB ([@bib7]) shRNAs subsequently transduced with CAPERα or TBX3 shRNAs. (**G**) % Quantitation of **A**--**F** from three replicate experiments. \* indicates p\<0.05 relative to Control or p53 shRNAs. (**H**) Cell proliferation assayed by crystal violet incorporation (OD units) in HFFs treated as in **A**--**F**. \* indicates p\<0.001 relative to Ctl or p53 shRNAs. (**I**--**L**) SA-βgal assays of HFFs stably transduced with control or p16 ([@bib25]) shRNAs subsequently transduced with CAPERα or TBX3 shRNAs. (**M**) % Quantitation of I-L from three replicate experiments. \* indicates p\<0.05 relative to Ctl shRNA. (**N**) Cell proliferation assayed by crystal violet incorporation (OD units) in HFFs treated as in **I**--**L**. \* indicates p\<0.01 relative to Ctl shRNA. (**O**) ChIP-PCR with antibodies listed at top on three regions upstream of the *CDKN2A-p16* transcriptional start site (TSS); position relative to (TSS) is indicated in parentheses at left of panels. PCR of input material used for the ChIP is shown under 'Input'. The shRNA transduced is listed above each lane (HFF Tx). TBX3 knockdown decreases binding of TBX3 (lanes 8) and CAPERα (lanes 11) to all three regions. CAPERα knockdown has minimal effect on TBX3 binding (lanes 9). Knockdown of either TBX3 or CAPERα decreases the repressive chromatin mark H3K9me3 (lanes14, 15) and increases the activating chromatin mark H3K4me3 (lanes 17, 18). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.009](10.7554/eLife.02805.009)10.7554/eLife.02805.010Figure 3---figure supplement 1.Effective knockdown of p53, RB and p16 in HFFs.(**A--C**) RT-PCR analysis of p53 (**A**), RB (**B**) and p16 (**C**) transcript levels relative to HPRT after shRNA-mediated KD in HFFs. The shRNAs employed for these knockdowns were obtained from Addgene and have been previously employed by numerous investigators ([@bib50]; [@bib7]; [@bib25]; [@bib29]; [@bib19]). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.010](10.7554/eLife.02805.010)10.7554/eLife.02805.011Figure 3---figure supplement 2.UCSC Genome Browser view of the *CDKN2A* locus and 5′ regions screened for binding by CAPERα and TBX3.Seven regions tested upstream of *CDKN2A-p16* promoter by ChIP with anti-TBX3 and anti-CAPERα antibodies. Amplicons are numbered black boxes 1--7 'Your Seq' at top superimposed on window from UCSC genome browser. Chromatin states in various cell types based are noted by colored bars below. Of these 7 regions, 3 were bound by both TBX3 and CAPERα: regions 3, 4 and 5 (data are presented in [Figure 3O](#fig3){ref-type="fig"}). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.011](10.7554/eLife.02805.011)10.7554/eLife.02805.012Figure 3---figure supplement 3.*CDKN2a-p16* H3K27 trimethylation markedly decreases in HFFS after knockdown of CAPERα or TBX3 consistent with activation of *CDKN2a-p16* expression.ChIP-PCR of *CDKN2A-p16* regulatory elements with anti-H3K27me3 in control, TBX3 or CAPERα shRNA-transduced HFFs. Locations of amplicons relative to transcription start site are noted in parentheses below each panel and correspond to regions 3, 4 and 5 in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.012](10.7554/eLife.02805.012)10.7554/eLife.02805.013Figure 3---figure supplement 4.Testing CAPERα and TBX3 binding to *p14, p21, CDK2, CDK4,* and *CDKN1B* regulatory elements.(**A**) ChIP-PCR of *CDKN2A-p14* promoter with antibodies listed at top in control (C) and TBX3 siRNA (C′) transduced HFFs. Red arrowhead indicates loss of CAPERα binding after TBX3 knockdown. (**B**--**E**) ChIP/PCR of HFF chromatin showing lack of TBX3 and CAPERα binding to known regulatory elements ([@bib2]; [@bib65]; [@bib49]) of: (B) *CDKN1A-p21* (location relative to transcription start site is noted in parentheses at the bottom of the panels (**C**) *CDK4* (**D**) *CDK2* (**E**) *CDKN1B*. TBX3, CAPERα = human; Tbx3, Caperα = mouse*.***DOI:** [http://dx.doi.org/10.7554/eLife.02805.013](10.7554/eLife.02805.013)

CAPERα/TBX3 regulates chromatin status of the *p16*^*INK*^ promoter {#s2-4}
-------------------------------------------------------------------

Increased p16 protein and RB hypophosphorylation in *Tbx3−/−* embryos and p16/RB-mediated senescence after CAPER*α* and TBX3 KD could result from loss of direct repression of *p16*^*INK*^ by CAPER*α*/TBX3 in proliferating cells. We screened 7 amplicons spanning ∼6 kb upstream of *p16*^*INK*^ by ChIP-PCR of HFF chromatin ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}); 3 amplicons were bound by CAPER*α* and TBX3 ([Figure 3O](#fig3){ref-type="fig"}, lanes 7, 10). Loss of either protein decreased the heterochromatic marks H3K9me3 ([Figure 3O](#fig3){ref-type="fig"}, lanes 14, 15) and H3K27me3 ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) and increased the euchromatic mark H3K4me3 ([Figure 3O](#fig3){ref-type="fig"}, lanes 17, 18). Notably, less CAPER*α* occupied *p16*^*INK*^ elements after TBX3 KD ([Figure 3O](#fig3){ref-type="fig"}, lanes 11) while the amount of TBX3 bound post-CAPER*α* KD was comparable to control ([Figure 3O](#fig3){ref-type="fig"}, lanes 9 vs 7). This is consistent with the abnormal localization of CAPER*α* seen in *Tbx3−/−* MEFS ([Figure 2---figure supplement 3D′--F′](#fig2s3){ref-type="fig"}) and indicates that CAPER*α* requires TBX3 to occupy *p16*^*INK*^ regulatory chromatin.

We examined whether CAPERα and/or TBX3 associate with promoters of other cell cycle genes that are transcriptionally dysregulated after CAPERα/TBX3 loss-of-function ([Figure 2K--M](#fig2){ref-type="fig"}). Antibodies against TBX3 and CAPER*α* ChIP\'d the *p14*^*ARF*^ initiator ([@bib46]) ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}); here too, TBX3 KD disrupted CAPERα binding ([Figure 3---figure supplement 4A′](#fig3s4){ref-type="fig"}, red arrowhead). Neither CAPERα nor TBX3 associated with amplicons scanning 1.8 kb upstream of *CDKN1A-p21* or elements reportedly bound by TBX2 or TBX3 in other cell types ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}) ([@bib56]; [@bib58]; [@bib30]). Testing for association with known regulatory elements of *CDK2*, *CDK4*, *CDKN1B* was also negative ([Figure 3---figure supplement 4C--E](#fig3s4){ref-type="fig"}) ([@bib2]; [@bib65]; [@bib49]). These data indicate that in proliferating primary cells, CAPERα/TBX3 specifically and directly repress the *CDKN2A* locus by binding multiple regulatory sequence elements and regulating chromatin marks.

Expression of the lncRNA *UCA1* is repressed by CAPERα/TBX3 and sufficient to drive senescence of primary cells {#s2-5}
---------------------------------------------------------------------------------------------------------------

To identify novel genes repressed by CAPERα/TBX3, we employed differential display to detect transcripts that increased in response to KD of TBX3 and CAPERα in HEK293 cells ([Figure 4A--C](#fig4){ref-type="fig"}). Although most transcripts were unaffected by either KD, or changes were not shared ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), *DUSP4* and *UCA1* were upregulated ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). DUSP4 is known to regulate cell survival and tumor progression, and overexpression induces senescence downstream of RB/E2F ([@bib63]; [@bib67]), thus placing CAPERα/TBX3 upstream of another p16/RB effector. Little is known about the function of the lncRNA *UCA1* ([@bib66], [@bib68]), so we investigated it further.10.7554/eLife.02805.014Figure 4.CAPERα/TBX3 directly represses expression of the long noncoding RNA *UCA1*.(**A**--**C**) Gel showing RT-PCR analysis of *TBX3, CAPERα,* and *HPRT* expression in control, TBX3 and CAPERα siRNA-transfected HEK293 cells. The siRNAs effectively decreased transcript levels of their targets. (**D**) Differential display: representative PAGE gel of cDNAs derived from random primed, RT-PCR\'d mRNAs from CAPERα, TBX3 and control siRNA transfected HEK293 cells. Blue arrowheads denote upregulated transcripts subsequently identified by sequencing as *DUSP4* and *UCA1*. (**E** and **F**) qPCR analysis of *TBX3* and *CAPERα* transcript levels in control and *TBX3* or *CAPERα* shRNA transduced HFFs (repeat of experiment shown in [Figure 2---figure supplements 1A and 2A](#fig2s1 fig2s2){ref-type="fig"}). (**G**) RT-PCR analysis of *UCA1* and *HPRT* gene expression in control, *TBX3* or *CAPERα* shRNA-transduced HFFs. (**H**) qPCR analysis of *UCA1* transcript levels in control, TBX3 or CAPERα shRNA transduced HFFs. Results confirm differential display result that KD of TBX3 or CAPERα results in increase in *UCA1* transcript levels. (**I**) Schematic representation of the *UCA1* locus with primer sets employed for ChIP-PCR amplification of denoted regions 5′ of gene (A1, A2, A3). (**J**) Anti-TBX3 ChIP-PCR of regions of the *UCA1* promoter in HFFs; only A3 is ChIP\'d by TBX3 (lane 18, red arrowhead). (**K**) Anti-CAPERα ChIP-PCR of regions of the *UCA1* promoter in HFFs; only A3 chromatin is ChIP\'d (lane 18, red arrowhead). (**L**) ChIP-PCR analysis of *UCA1/*A3 chromatin from in HFFs transduced with control (C) or TBX3 (KD) shRNA; ChIP antibodies are listed at top. Note decreased CAPERα binding after TBX3 KD (lane 17, red arrowhead), gain of activating mark H3K4me3 and loss of repressive marks H3K9me3 and H3K27me3. (**M**) ChIP-PCR analysis of *UCA1/*A3 with antibodies listed at top of panel in HFFs transduced with control (C) or *CAPER*α shRNAs. Note continued TBX3 binding despite *CAPER*α KD (lane 11, red arrowhead) and changes in chromatin marks parallel those seen in with TBX3 KD in panel **L**. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.014](10.7554/eLife.02805.014)10.7554/eLife.02805.015Figure 4---figure supplement 1.Validation of differential display findings.(**A**) Additional representative differential display gels with transcripts unchanged or independently affected by knockdown of CAPER*α* or TBX3 in HEK293 cells. (**B**) RT-PCR validating differential display result of increased *DUSP4* transcripts ([Figure 4D](#fig4){ref-type="fig"}) after CAPER*α* or TBX3 KD in HEK293 cells. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.015](10.7554/eLife.02805.015)

We found that shRNA KD of CAPERα or TBX3 in primary HFFS recapitulated the increase in *UCA1* transcripts seen in HEK293 cells ([Figure 4E--H](#fig4){ref-type="fig"}). We then tested whether CAPERα/TBX3 directly control transcription of *UCA1* by interacting with potential regulatory elements. Public ChIP data ([http://genome.ucsc.edu/](http://genome.ucsc.edu/index.html)) indicate that the 2 kb upstream of *UCA1* may contain such elements. We assayed 3 amplicons in this region ([Figure 4I](#fig4){ref-type="fig"}: A1, A2, A3) by ChIP-PCR of TBX3 and CAPERα: only region A3 was bound ([Figure 4J,K](#fig4){ref-type="fig"}, lanes 18, red arrowheads).

We next determined whether increased *UCA1* expression in response to KD of CAPERα or TBX3 was associated with altered chromatin structure (as seen with *p16*^*INK*^, [Figure 3O](#fig3){ref-type="fig"}). *UCA1/A3* is normally in a heterochromatin configuration in HFFs, with repressive marks H3K9me3 and H3K27me3 ([Figure 4L](#fig4){ref-type="fig"}, lanes 12, 14) and little H3K4me3 ([Figure 4L](#fig4){ref-type="fig"}, lane 18). After TBX3 KD, activating chromatin marks replaced repressive ones ([Figure 4L](#fig4){ref-type="fig"}, lanes 13, 15 and 19) and markedly less CAPERα was bound ([Figure 4L](#fig4){ref-type="fig"}, lane 17, red arrowhead). CAPERα KD also led to loss of repressive marks on *UCA1/A3* ([Figure 4M](#fig4){ref-type="fig"} lanes 9, 16), although TBX3 remained bound ([Figure 4M](#fig4){ref-type="fig"}, lane 11, red arrowhead). Combined with previous findings, we conclude that: (1) TBX3 recruits CAPERα to *UCA1/A3* chromatin, (2) TBX3 alone is insufficient to repress *UCA1* and, (3) the default state of *UCA1* in proliferating HFFs is repression conferred by CAPERα/TBX3.

*UCA1* modulates behavior of bladder cancer cell lines ([@bib68]), but there are no data on its function in primary cells; our results suggest that *UCA1* may be involved in premature senescence. *UCA1* transcripts are low in proliferating HFFs, but 4 days after overexpression of *UCA1* ([Figure 5A](#fig5){ref-type="fig"}), a robust SA-βgal response is evident ([Figure 5B--D](#fig5){ref-type="fig"}). Cells constitutively expressing *UCA1* ceased proliferating during selection and accumulated SAHFs ([Figure 5E,F](#fig5){ref-type="fig"}). Cell proliferation decreased in a *UCA1* dosage-sensitive manner ([Figure 5G--I](#fig5){ref-type="fig"}), consistent with reduced levels of cell cycle promoting transcripts and increased levels of pro-senescence ones ([Figure 5J](#fig5){ref-type="fig"}). These transcriptional changes were manifest at the protein level ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Premature senescence resulting from overexpression of *UCA1* in HFFs reveals that this lncRNA is a novel regulator of cell proliferation and may function as a tumor suppressor in some contexts.10.7554/eLife.02805.016Figure 5.*UCA1* expression is sufficient to induce senescence and required for normal execution of oncogene-induced senescence.(**A**) *UCA1* and *HPRT* transcripts assessed by RT-PCR in control and *UCA1-*overexpressing HFFs. (**B** and **C**) Representative bright field images of SA-βgal assay of cultured HFFs transfected with control and *UCA1* overexpression plasmids. (**D**) % quantitation of SA-βgal cells from five replicates in control and *UCA1* overexpressing HFFs. \* indicates p\<0.05. (**E** and **F**) Immunohistochemical analysis reveals co-localization of H3K9me3 and DAPI in SAHFs in HFFs transfected with *UCA1* overexpression plasmid (**F**) but not control plasmid (**E**). (**G**) Cell count of control and *UCA1* overexpressing HFFs 3 days post transfection. Mean ± SD of 3 plates is shown at each time point. \* indicates p\<0.005 relative to control. (**H**) Crystal violet assay of cell growth in control and *UCA1* overexpressing HFFs transfected with 2 μg of expression or control vector and assayed daily for 3 days post- transfection. \* indicates p\<0.01 relative to control. (**I**) Crystal violet assay of HFFs cultured for 3 days after transfecting 0, 1, 2, or 4 μg of control or *UCA1* overexpression plasmid. \* indicates p\<0.01 relative to control. (**J**) Transcript levels assessed by qPCR; values reflect fold change in *UCA1-*overexpressing HFFs relative to control after normalization to *HPRT* levels. \* indicates p\<0.05 relative to control. (**K**) qPCR analysis of *UCA1* expression in untransduced, presenescent (PS) HFFs and HFFs transduced with constitutively active G12VRAS (RAS). \* indicates p\<0.05 relative to PS. (**L**) Efficient knockdown of *UCA1* transcripts in RAS HFFs with *UCA1* shRNA (quantitated in panel **T**). (**M**--**P**) SA-βgal assays of RAS HFFs transduced with either control or *UCA1* shRNA at 3 (**M** and **O**) and 5 (**N** and **P**) days post transduction. (**Q**) % quantitation of SA-βgal cells from six replicate experiments as represented in panels **M**--**P**. \* indicates p\<0.001 relative to control. (**R**) % quantitation of Ki67 + cells from three replicates in control vs *UCA1* shRNA transduced RAS HFFs. \* indicates p\<0.001 relative to control. (**S**) RT-PCR for *UCA1* transcripts shows persistent knockdown of *UCA1* in RAS shRNA cells with increasing passage (P0--P2). (**T**) qPCR analysis of fold changes in transcript levels of cell cycle and senescence genes after *UCA1* shRNA knockdown in RAS HFFs. \* indicates p\<0.05 relative to control. (**U**) ChIP-PCR analysis of *UCA1* region A3 with antibodies listed at top in PS and RAS HFFs. Note gain of activating (H3K4me3, H3K9ace, H4K5ace) and loss of repressive marks (H3K9me3, H3K27me3) at the *UCA1* locus after oncogene-induced senescence by RAS. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.016](10.7554/eLife.02805.016)10.7554/eLife.02805.017Figure 5---figure supplement 1.Western blots showing changes in protein levels in response to *UCA1* overexpression in HFFs.pcDNA3.1 are control transfected cells and UCA1 were transfected with *UCA1* expression plasmid in pcDNA3.1 (as in [Figure 5A](#fig5){ref-type="fig"}). Note increased p16 and p21 levels and hypophosphorylation of RB. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.017](10.7554/eLife.02805.017)10.7554/eLife.02805.018Figure 5---figure supplement 2.ChIP-PCR assay for H3K9 acetylation of known regulatory elements of prosenescence and cell cycle genes whose expression is dyregulated after *UCA1* overexpression.Input, rabbit IgG negative control ChIP, and H3K9acetylation ChIP in control "C" or *UCA1* "U" transfected HFFs for gene regulatory regions as labeled at bottom (primer sequences listed in ChIP primers section of methods). P16 a and b refer to amplicons --(2457--2040) and --(3107--2710), respectively. No changes in H3K9ace levels were detected in response to *UCA1* overexpression, suggesting that altered chromatin structure and subsequent increased transcription are not the cause of observed changes in transcript levels detected with UCA1 overexpression and shown in [Figure 5J](#fig5){ref-type="fig"}. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.018](10.7554/eLife.02805.018)

Loss of *UCA1* delays the onset of oncogene-induced senescence {#s2-6}
--------------------------------------------------------------

We tested the hypothesis that *UCA1* is required for induction of oncogene-induced senescence (OIS) in primary cells ('RAS': HFFs transduced with constitutively active ^G12V^RAS \[[@bib60]\]). There are markedly more *UCA1* transcripts in RAS compared to presenescent 'PS' HFFs ([Figure 5K](#fig5){ref-type="fig"}). Knockdown of *UCA1* in RAS HFFs reduced SA-βgal activity ([Figure 5L--Q](#fig5){ref-type="fig"}) and improved RAS cell growth: the number of Ki67 + RAS cells was increased at days 3 and 6 after *UCA1* KD ([Figure 5R](#fig5){ref-type="fig"}, P0 and P1). However, by passage 2, the number of Ki67 + cells was not statistically different in *UCA1* KD cells from control, despite persistently low levels of *UCA1* ([Figure 5S](#fig5){ref-type="fig"}) and decreased levels of pro-senescence transcripts ([Figure 5T](#fig5){ref-type="fig"}). Overall, this indicates that senescence can occur in the absence of high levels of UCA1 but that timely execution of the OIS program requires *UCA1*.

We next investigated whether increase in *UCA1* transcripts in OIS is a manifestation of loss of CAPERα/TBX3 occupancy/repression of *UCA1/A3*. Indeed, the repressor dissociates from *UCA1/A3* in RAS HFFs and *UCA1/A3* chromatin switches from heterochromatic to euchromatic marks ([Figure 5U](#fig5){ref-type="fig"}). This is consistent with the senescence-inducing effects of CAPERα/TBX3 loss-of-function ([Figure 2](#fig2){ref-type="fig"}) and resulting upregulation of *UCA1* ([Figure 4](#fig4){ref-type="fig"}), and establishes CAPERα/TBX3 regulation of *UCA1* in an independent model of senescence.

*UCA1* promotes senescence by sequestering hnRNP A1 to stabilize *p16*^*INK*^ mRNA {#s2-7}
----------------------------------------------------------------------------------

Some lncRNAs influence transcription by recruiting chromatin modifiers to target genes ([@bib21]). We tested whether the increased levels of prosenescence transcripts occurring in response to *UCA1* ([Figure 5J](#fig5){ref-type="fig"}) were the result activating chromatin changes however, ChIP-PCR assay for H3K9 acetylation of the *p16*^*INK*^*, p14*^*ARF*^, *CDKN1A-p21* (and other) promoters did not reveal changes in this activating mark in response to *UCA1* ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). We thus tested whether altered mRNA stability contributed to the observed changes. HFFs were transfected with *UCA1* expression or control plasmid and after 2 days, treated with Actinomycin D. Total RNA was collected at 0--4 hr post-treatment and mRNA levels assayed using RT-PCR. Remarkably, overexpression of *UCA1* resulted in the stabilization of mature *p16*^*INK*^*, p14*^*ARF*^*, E2F1,* and *TGFβ1* mRNAs: in the time frame examined, *p16*^*INK*^, *p14*^*ARF*^, and *E2F1* mRNAs do not decay and their t~1/2~ values are therefore denoted as 'n' (no decay). The half-life estimates shown were calculated using linear regression; those best fit lines, their equations and R values are shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. t~1/2~ of *p16*^*INK*^ mRNA in control cells was 3.9 hr vs n in *UCA1* overexpressing cells; *p14*^*ARF*^, 2.4 vs n; *E2F1,* 7.2 vs n; *TGFβ1,* 1.9 vs 2.9. In marked contrast, *MYC, CDKN1A-p21*, *CDKN2D* and *RB* mRNAs decayed at rates indistinguishable from control ([Figure 6A](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The effects of *UCA1* overexpression on *p16*^*INK*^ mRNA stability were confirmed by Northern blot ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).10.7554/eLife.02805.019Figure 6.UCA1 stabilizes CDKN2A-p16 mRNA levels during senescence by sequestering hnRNP A1.(**A**) Graphs of transcript levels assayed by RT-qPCR in HFFs transfected with control (blue) or *UCA1* (red) expression plasmids and treated with Actinomycin (**D**). Y axis shows % mRNA level relative to time zero and X axis shows time in hours assayed post treatment. The estimated half-lives (t~1/2~) were obtained using linear regression; the best fit lines, their equations and R values are shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. \* indicates p\<0.04 for *p16*^*INK*^ and p\<0.01 for all others. (**B**) Assay of mRNA levels in HFFs transfected with control or hnRNPA1 siRNA and treated with Actinomycin D. Axes and t~1/2~ calculations are as in panel **A**. \* indicates p\<0.05. (**C**--**E**) Agarose gels of RT-PCR products assessing levels of *CDKN2A-p16* (p16, panel **C**), *UCA1* (panel **D**), and negative control lncRNA *TUG1* (panel **E**) transcripts in PS and RAS HFFs treated as labeled at top and subjected to RIP with anti-hnRNPA1 antibody. mIgG lanes are negative controls for RIP assays. Gels from left to right show: PS vs RAS; control vs *UCA1* overexpression; control vs TBX3 or CAPERα knockdown; RAS vs RAS/*UCA1* knockdown. (**C**) Lane 7 (red arrowhead) shows loss of *p16*^*INK*^ /hnRNP A1 interaction in RAS. Lane 14 (red arrowhead) shows loss of *p16*^*INK*^ /hnRNP A1 interaction with *UCA1* overexpression. Lanes 23 and 24 show loss of *p16*^*INK*^ /hnRNP A1 interaction after TBX3 or CAPERα knockdown. Lane 27 shows that *UCA1* knockdown decreases the total amount of *p16*^*INK*^ mRNA in RAS cells. Lane 31 shows that *UCA1* knockdown increases *p16*^*INK*^ mRNA/hnRNP A1 binding (red arrowhead) in RAS cells, even though there is less total *p16*^*INK*^ (lane 27). (**F**) Panels show immunoblots to detect hnRNP A1 protein in input samples assayed in panels **C**--**E**. Lanes are numbered to correspond with panels above. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.019](10.7554/eLife.02805.019)10.7554/eLife.02805.020Figure 6---figure supplement 1.Graphs showing best fit lines, their equations, and R values used to calculate estimated mRNA half-life values shown in [Figure 6A](#fig6){ref-type="fig"}.TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.020](10.7554/eLife.02805.020)10.7554/eLife.02805.021Figure 6---figure supplement 2.Northern blot assay of *p16*^*INK*^ mRNA levels in the absence and presence of *UCA1*.(**A**) Top panel shows Northern blot of HFF cells transfected with control plasmid pcDNA3.1 and treated with Actinomycin D for the times (hr) indicated at top. (**A′**) The ethidum bromide stained gel prior to transfer is shown for loading control and RNA quality. (**A″**) The signals obtained by probing for *p16*^*INK*^ mRNA in **A** were subjected to densitometric quantitation. Note decrease in signal at 2 and 4 hr consistent with the decay/t~1/2~ obtained in [Figure 6A](#fig6){ref-type="fig"}. (**B**) Top panel shows Northern blot of HFF cells transfected with UCA1 expression plasmid and treated with Actinomycin D for the times (hr) indicated at top. (**B′**) The ethidum bromide stained gel prior to transfer is shown for loading control and RNA quality. (**B″**) The signals obtained by probing for *p16*^*INK*^ mRNA in **B** were subjected to densitometric quantitation. Note that *UCA1* expression results in minimal decrease in signal at 2 and 4 hr, consistent with *UCA1*-mediated mRNA stabilization observed in [Figure 6A](#fig6){ref-type="fig"}. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.021](10.7554/eLife.02805.021)10.7554/eLife.02805.022Figure 6---figure supplement 3.Graphs showing best fit lines, their equations and R values used to calculate estimated half-life values after hnRNP A1 siRNA knockdown shown in [Figure 6B](#fig6){ref-type="fig"}.(**A**) Western blot assaying hnRNP A1 protein levels in HFFs after transfection of control or anti-hnRNP A1 siRNA. (**B**) Graphs of best fit lines, equations and R values for half-lives shown in [Figure 6B](#fig6){ref-type="fig"}. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.022](10.7554/eLife.02805.022)10.7554/eLife.02805.023Figure 6---figure supplement 4.RNA Immunoprecipitation analysis of hnRNP A1 interactions with *Myc* and *p14ARF* mRNAs.RIP-PCR of *MYC* and *CDKN2A-p14* mRNAs shows they are bound by hnRNP A1 but these interactions are unaffected by OIS/RAS, *UCA1* overexpression, or knockdown of TBX3 or CAPER*α*. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.023](10.7554/eLife.02805.023)10.7554/eLife.02805.024Figure 6---figure supplement 5.RIP-PCR of HFF lysates using antibodies listed at top.Only hnRNP A1 (**A**) and hnRNP D (**B**) bind *UCA1* lncRNA, while *TUG1* and *H19* lncRNAs are bound by other hnRNPs. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.024](10.7554/eLife.02805.024)10.7554/eLife.02805.025Figure 6---figure supplement 6.RIP-PCR indicates that *RB, p21,* and *CDK6* mRNAs do not interact with hnRNP A1 in PS or RAS HFFs.TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.025](10.7554/eLife.02805.025)

Regulation of *p16*^*INK*^ transcript stability is a critical mechanism for growth control ([@bib65]; [@bib10]; [@bib73]) and hnRNP A1 has been postulated to stabilize *p16*^*INK*^ mRNA ([@bib74]), but this has not been tested. To this end, we treated HFFs with siRNA to hnRNP A1 and used Actinomycin D to assess stability of *p16*^*INK*^ transcripts. Loss of hnRNP A1 ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}) stabilized both *p16*^*INK*^ (t~1/2~--2.1 in control vs 12.3 after HNRNP A1 knockdown) and *p14*^*ARF*^ mRNAs (t~1/2~--1.5 in control vs 6.9 after hnRNP A1 knockdown) but not those of *E2F1* or *MYC* ([Figure 6B](#fig6){ref-type="fig"}). Half-life estimates were obtained as described for panel A and the best fit lines, their equations and R values are shown in [Figure 6---figure supplement 3B](#fig6s3){ref-type="fig"}. The differences in control half-lives between [Figure 6A,B](#fig6){ref-type="fig"} are likely attributable to the different treatments used: in A, control cells were transfected with pcDNA3.1 plasmid, while in B, control cells were transfected with control siRNA. The half-life of an mRNA is cell/context specific (as evident in the differences in control half-lives in 6A vs 6B) and in general, cell cycle regulatory genes have short half-lives ([@bib61]). The t~1/2~ of *p16*^*INK*^ mRNA we observed in HFFs transfected with either control plasmid (t~1/2~--3.9) or control siRNA (t~1/2~--2.1) is similar to that reported in HeLa cells (t~1/2~--2.9) ([@bib10]). The results we obtained were also similar to those reported for *MYC* mRNA ([@bib28]; [@bib61]), *CDKN1A* mRNA in HT29-tsp53 cells ([@bib51]) and ES cells ([@bib61]), and *E2F1* mRNA in ES cells ([@bib61]). The half- lives of *Rb* and *TGFβ1* are mRNAs extremely variable and those we obtained in HFFs were shorter than reported in ES cells ([@bib61]).

We next used RNA-IP (RIP) to determine if hnRNP A1 binds *p16*^*INK*^ and *p14*^*ARF*^ mRNAs in proliferating cells and found that this was indeed the case ([Figure 6C](#fig6){ref-type="fig"}, lane 6 and [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Remarkably, hnRNP A1/*p16*^*INK*^ binding was lost in RAS HFFs ([Figure 6C](#fig6){ref-type="fig"}, lane 7), despite an overall increase in the number of *p16*^*INK*^ transcripts ([Figure 6C](#fig6){ref-type="fig"}, lane 3). As shown previously, *UCA1* RNA levels also increase with RAS ([Figure 6D](#fig6){ref-type="fig"}, lane 3). *UCA1* is bound by hnRNP A1 in PS cells ([Figure 6D](#fig6){ref-type="fig"}, lanes 6, 7; [Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}), but unlike *p16*^*INK*^, the hnRNP A1/*UCA1* interaction increases in RAS cells ([Figure 6D](#fig6){ref-type="fig"}, lane 7). *TUG1* lncRNA serves as a negative control ([Figure 6E](#fig6){ref-type="fig"}). Protein levels for hnRNP A1 are shown in [Figure 6F](#fig6){ref-type="fig"}. The interaction between *UCA1* and hnRNP A1 is specific, as *UCA1* does not bind hnRNP K, C1/C2, H, U, or D ([Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}). Although hnRNP A1 binds *MYC* and *p14ARF* mRNAs ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}), it does not bind *RB*, *p21* or *CDK6* mRNAs under the numerous conditions tested ([Figure 6---figure supplement 6](#fig6s6){ref-type="fig"}).

The opposite binding properties of *UCA1* and *p16*^*INK*^ mRNA with hnRNP A1 in PS vs RAS HFFs led us to postulate that *UCA1* stabilizes *p16*^*INK*^ mRNA during OIS by disrupting the interaction between hnRNP A1 and *p16*^*INK*^ mRNA. In control transfected proliferating cells, there is robust binding of *p16*^*INK*^ to hnRNP A1 ([Figure 6C](#fig6){ref-type="fig"}, lane13), but direct overexpression of *UCA1* ([Figure 6D](#fig6){ref-type="fig"}, lane 10) or that resulting from TBX3 or CAPERα KD ([Figure 6D](#fig6){ref-type="fig"}, lanes 17, 18) disrupts the hnRNP A1/*p16*^*INK*^ mRNA interaction ([Figure 6C](#fig6){ref-type="fig"}, lanes14, 23, 24, red arrowheads). These findings support the hypothesis that loss of hnRNP A1/*p16*^*INK*^ mRNA interaction in OIS ([Figure 6C](#fig6){ref-type="fig"}, lane 7) is the result of increased *UCA1* expression and its binding and sequestration of hnRNP A1 ([Figure 6D](#fig6){ref-type="fig"}, lane 7). To further test this, we used shRNA to KD *UCA1* in RAS HFFs ([Figure 6D](#fig6){ref-type="fig"}, lane 27). *UCA1* KD restored the interaction between hnRNP A1 and *p16*^*INK*^ mRNA ([Figure 6C](#fig6){ref-type="fig"}, lane 31) and led to lower levels of total *p16*^*INK*^ mRNA ([Figure 6C](#fig6){ref-type="fig"}, lane 27), a finding consistent with the negative effects of hnRNP A1/ *p16*^*INK*^ interaction on stability of *p16*^*INK*^ transcripts. The effects of *UCA1* on *p16*^*INK*^ mRNA stability are specific, because hnRNP A1 interactions with *MYC* or *p14*^*ARF*^ mRNAs are unaffected by *UCA1* ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

In total, these findings indicate that in proliferating cells, the very low quantity of *UCA1* transcripts is insufficient to disrupt hnRNP A1/*p16*^*INK*^ binding, and levels of *p16*^*INK*^ mRNA are low due to: (1) direct repression by CAPERα/TBX3 and, (2) *p16*^*INK*^ mRNA instability conferred by hnRNP A1. When *UCA1* levels increase during OIS, by *UCA1* overexpression, or via KD of CAPERα/TBX3, *UCA1* binds and sequesters hnRNP A1, preventing it from destabilizing *p16*^*INK*^ mRNA.

The CAPERα/TBX3 co-repressor dissociates during oncogene-induced senescence leading to activation of *UCA1* and pro-senescence pathways {#s2-8}
---------------------------------------------------------------------------------------------------------------------------------------

Increased p16 protein is required for RAS-induced senescence in MEFS and some human cell types ([@bib60]), leading us to determine whether OIS affects CAPERα/TBX3 occupancy of *p16*^*INK*^ chromatin. *CDKN2A-p16*^*INK*^ genomic regulatory elements bound in PS HFFs ([Figure 4I](#fig4){ref-type="fig"}) were not occupied by either TBX3 or CAPER*α* in RAS HFFs ([Figure 7A](#fig7){ref-type="fig"}). Chromatin marks on these regions switched from heterochromatic to euchromatic ([Figure 7B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). This was also observed with *UCA1/A3* ([Figure 5U](#fig5){ref-type="fig"}) and *DUSP4* chromatin ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}).10.7554/eLife.02805.026Figure 7.Disruption of the CAPERα/TBX3 repressor by OIS activates *CDKN2A-p16* and *UCA1* to trigger a senescence transcriptional response.(**A**) ChIP-PCR of regions upstream of the *CDKN2A-p16* transcriptional start site (position relative to TSS in parentheses) in PS and RAS HFFs; the −-3706--3308 amplicon is a negative control. OIS disrupts binding of *p16* regulatory elements (initially identified in [Figure 3O](#fig3){ref-type="fig"}) by TBX3 and CAPERα. (**B**) ChIP-PCR of *p16* -4855 element shown in **A**. Decreased TBX3 and CAPERα binding in RAS correlates with loss of repressive chromatin marks and gain of activating marks. Evaluation of chromatin marks on the other *CDKN2A-p16* CAPERα/TBX3- responsive regulatory elements is shown in [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}. (**C**) IBs for TBX3, CAPERα, and actin loading control show increased amount of both proteins in RAS compared to PS HFFs. (**D**) Anti-TBX3 and anti-CAPERα IBs of IP\'d proteins from PS and RAS HFFs. (**F**--**M**) Immunocytochemical staining of PS (**F**, **G**, **J**, **K**) and RAS (**H**, **I**, **L**, **M**) HFFS for TBX3 (**F** and **H**), Hoechst (DNA; **G** and **I**), CAPER*α* (**J** and **L**). Panels **K** and **M** are merged Hoechst/CAPER*α*. Scale bar for all panels is sown at lower right of panel **I**. (**N**--**O′**) Functional analyses of genome wide transcriptional profiles of TBX3 KD, CAPERα KD, and control HFFs. All comparisons were statistically significant with p values \<\<\<\<0.0001; see [Figure 7---source data 3](#SD3-data){ref-type="supplementary-material"} for hypergeometric test, as implemented in the R statistical language, used to test significance of the number of genes found to be co-regulated between samples. (**N**) Venn diagrams show highly significant number of CAPERα/TBX3 co-upregulated transcripts (446 total), especially in the GO biologic process (BP) category of transcriptional regulation (122 transcripts) as assayed with DAVID. Pie chart shows KEGG pathway analysis of co-regulated genes. (**N′**) Venn diagram showing 48 CAPERα/TBX3 co-upregulated transcripts also upregulated by RAS/OIS ([@bib48]), especially in BP categories of transcriptional regulation and programmed cell (pc) death. qPCR validation of coregulated genes is in **S**. [Figure 6A](#fig6){ref-type="fig"}. Pie chart shows KEGG pathway analysis of OIS dataset. (**O** and **O′**) As in **N** and **N′** but for downregulated genes. Pie chart in **O′** shows KEGG pathway analysis of OIS data set; note most pathways are the same as in TBX3/CAPERα. (**P** and **Q**) Models of CAPERα/TBX3 repressor and *UCA1* function in proliferating (PS) HFFs vs RAS HFFs. In PS cell nuclei, CAPERα/TBX3 represses *UCA1, p16, p14,* and *DUSP4* promoters in heterochromatin which permits ongoing cell proliferation. RAS disrupts the CAPERα/TBX3 complex and CAPER*α* relocates to dense intranuclear foci. Pro-senescence genes including *UCA1* and *p16* are converted to euchromatin and their expression/products induce senescence. In the cytoplasm of PS cells, hnRNP A1 binds and destabilizes *p16* mRNA, but activation of *UCA1* expression in OIS allows *UCA1* to sequester hnRNP A1 and stabilize *p16* mRNA. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.026](10.7554/eLife.02805.026)10.7554/eLife.02805.027Figure 7---source data 1.Differentially expressed genes after knockdown of CAPERα in HFFs detected by RNA-Seq.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.027](10.7554/eLife.02805.027)10.7554/eLife.02805.028Figure 7---source data 2.Differentially expressed genes after knockdown of TBX3 in HFFs detected by RNA-Seq.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.028](10.7554/eLife.02805.028)10.7554/eLife.02805.029Figure 7---source data 3.Determining the statistical significance of shared differentially expressed genes using the hypergeometric test, as implemented in the R statistical language (phyper).**DOI:** [http://dx.doi.org/10.7554/eLife.02805.029](10.7554/eLife.02805.029)10.7554/eLife.02805.030Figure 7---figure supplement 1.Repression of *CDKN2A-p16* and *DUSP4* by CAPER*α* /TBX3 correlates with chromatin architecture and is relieved during oncogene induced senescence.(**A**) ChIP-PCR to assess chromatin marks on *CDKN2A-p16* regulatory elements in PS and RAS HFFs; antibodies are listed at top. (**B**) ChIP-PCR of *DUSP4* promoter in PS and RAS HFFs; antibodies are listed at top. TBX3 and CAPERα bind the *DUSP4* promoter in PS (lanes 6, 8) but not RAS HFFs (lanes 7, 9), and their occupancy correlates with altered chromatin marks consistent with de-repression in OIS/RAS cells (lanes 10--15). TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.030](10.7554/eLife.02805.030)10.7554/eLife.02805.031Figure 7---figure supplement 2.CAPER*α* relocalization due to oncogene-induced senescence is independent of PML bodies.Immunocytochemical assay for endogenous CAPER*α* (green), PML (red), and DNA (DAPI, blue) in PS and RAS HFFs. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.031](10.7554/eLife.02805.031)10.7554/eLife.02805.032Figure 7---figure supplement 3.Validation of RNA-Seq identified expression changes induced by CAPER*α* and TBX3 KD.qPCR validation of a subset of transcripts with altered expression detected by genome wide RNA-Seq on cDNA prepared from CAPER*α* (red) and TBX3 (blue) KD, and RAS HFFs (green). Downregulated transcripts are listed at left, upregulated at right. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.032](10.7554/eLife.02805.032)10.7554/eLife.02805.033Figure 7---figure supplement 4.IL6 and HDAC9 are direct targets of CAPER*α*/TBX3.ChIP-PCR with antibodies listed at top showing CAPER*α*/TBX3 directly binds *IL6* (and *HDAC9*) control elements. Effects of TBX3 or CAPER KD on chromatin marks are shown compared with control KD. ChIP-PCR examining CAPER*α*/TBX3 binding to *IL6* and *HDAC9* control elements in PS and RAS HFFs; loss of binding correlates with altered chromatin marks. TBX3, CAPERα = human; Tbx3, Caperα = mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.02805.033](10.7554/eLife.02805.033)

We investigated the possibility that altered quantity of either CAPERα or TBX3 could disrupt the stoichiometry of their interaction and cause dissociation from *p16*^*INK*^ and *UCA1* regulatory elements in OIS. Surprisingly, both TBX3 and CAPERα protein levels were increased in RAS HFFs ([Figure 7C](#fig7){ref-type="fig"}), but they no longer co-IP\'d ([Figure 7D](#fig7){ref-type="fig"}, red box). Immunocytochemistry of endogenous TBX3 and CAPERα in PS and RAS HFFs confirmed increased protein levels in OIS ([Figure 7F--M](#fig7){ref-type="fig"}), and revealed dramatic changes in CAPER*α* localization: CAPER*α* immunoreactivity became concentrated in large intranuclear foci ([Figure 7L,M](#fig7){ref-type="fig"}), as we previously observed in early passage *Tbx3−/−* MEFS ([Figure 2---figure supplement 2D--F′](#fig2s2){ref-type="fig"}). These foci are distinct from SAHFs and PML bodies ([Figure 7M](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

To further investigate the molecular basis of senescence initiation after loss of CAPERα/TBX3, we performed genome-wide transcriptional profiling 2 days post CAPER*α*, TBX3 and control KD in HFFs. More than half of the transcripts with expression altered 1.5-fold or more by CAPER*α* KD were similarly affected by loss of TBX3 (N = 2375 CAPER*α* KD, 2188 TBX3 KD; 1157 co-regulated, p\<\<\<\<0.0001, [Figure 7---source data 1--3](#SD1-data SD2-data SD3-data){ref-type="supplementary-material"}, [Figure 7N,O](#fig7){ref-type="fig"}). Gene ontology-biologic process (GO-BP) analysis with DAVID ([@bib32], [@bib31]) showed highly significant co-regulation of 'transcription regulation' (increased expression) and 'cell-cycle' (decreased expression) transcripts ([Figure 7N,O](#fig7){ref-type="fig"}). We tested a subset of these with known roles in senescence by qPCR: 100% validated and were similarly altered by RAS ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). Further interrogation of this group revealed that *IL6* and *HDAC9* are CAPERα/TBX3 direct targets and their upregulation in RAS is associated with loss of CAPERα/TBX3 binding ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}).

We compared CAPERα/TBX3 co-regulated transcripts to a published data set comparing PS and ^G12V^RAS fibroblasts ([@bib48]). This revealed that 11% of CAPERα/TBX3 up-regulated transcripts were also increased by RAS ([Figure 7N′](#fig7){ref-type="fig"}); among these, GO-BP 'programmed cell death' (31%) and 'transcription regulation' (34%) were highly overrepresented. 30% of CAPERα/TBX3 down-regulated transcripts were also in the RAS data set; \>1/3 of these were cell cycle genes ([Figure 7O′](#fig7){ref-type="fig"}). In all comparisons, the number of transcripts common to both groups was greater than predicted by chance and highly statistically significant ([Figure 7---source data 3](#SD3-data){ref-type="supplementary-material"}). KEGG pathway analyses revealed overrepresented pathways that were common to both CAPERα/TBX3 and RAS data sets ([Figure 7N--O′](#fig7){ref-type="fig"}, pie charts), but notably fewer pathways were shared in the upregulated group: JAK/STAT, TLR and TGFβ signaling pathways were only significantly overrepresented in the CAPERα/TBX3 data set.

Discussion {#s3}
==========

Our knowledge of the regulatory mechanisms that govern the onset and maintenance of senescence in different contexts must be considered fragmentary ([@bib64]; [@bib21]). In this study, we provide compelling evidence for critical and novel functions of CAPERα, the lncRNA *UCA1* and TBX3 in the regulation of cell proliferation and senescence. We have discovered a CAPERα/TBX3 complex that is required to prevent senescence of primary human and mouse cells in vivo and that functions as a master regulator of cell proliferation by directly repressing transcription of lncRNA *UCA1*, *p16*^*INK*^ and other tumor suppressor genes ([Figure 7P](#fig7){ref-type="fig"}). Overexpression of *UCA1* occurs after loss of TBX3/CAPER*α* and in OIS ([Figure 7Q](#fig7){ref-type="fig"}), and is itself sufficient to induce senescence at least in part, by disrupting the interaction of *p16*^*INK*^ mRNA with hnRNP A1 leading to increased *p16*^*INK*^ mRNA stability ([Figure 7P,Q](#fig7){ref-type="fig"}). Disrupting the CAPERα/TBX3 complex by decreasing the amount of either TBX3 or CAPER*α*, or by CAPER*α* mislocalization during OIS, coordinately increases activity of multiple pro-senescence targets at both the transcriptional and post-transcriptional levels in a reinforcing mechanism.

Increased CAPER*α* has been reported in human breast cancers and a shift from cytoplasmic to nuclear localization correlates with transition from pre-malignant to malignant lesions ([@bib52]). In contrast, CAPERα co-activates vRel mediated transcription but inhibits vREL transforming activity in vitro ([@bib18]). It is likely that anti- or pro- oncogenic activity of CAPER*α* is determined by cell type and the interacting protein(s) present in a given context; our results suggest that CAPER*α* has oncogenic potential in primary cells since loss of CAPERα/TBX3 induces premature senescence, a vital tumor suppressor mechanism. CAPER*α* binds to regulatory chromatin domains via TBX3 but dissociates from these domains and becomes concentrated in large intranuclear foci prior to senescence induced by loss of TBX3 or during OIS. Future efforts will define the composition of CAPER + nuclear foci and the role of this nuclear subdomain during senescence induction.

The TBX3 RD is required for TBX3 to interact with CAPERα (this study), immortalize primary fibroblasts and confer senescence bypass ([@bib9]). Since loss of CAPERα activates target gene transcription despite continued TBX3 occupancy, it is the CAPERα/TBX3 complex (interacting via TBX3 RD) that represses pro-senescence target loci. It will be important to determine if previously identified targets of TBX3 transcriptional repression are actually regulated by this complex.

Additional studies are warranted to determine the precise mechanisms whereby histone status is regulated by CAPERα/TBX3: TBX3 is known to interact directly with HDACs ([@bib70]), but there are no reports of it or CAPERα interacting with histone methyltransferases or demethylases. Our recently published Mass Spec screen for Tbx3/TBX3 interactors did not identify such factors however, the screen cannot be considered exhaustive as we did not reproducibly detect HDACs or transcription factors previously reported to interact with Tbx3. Future studies to specifically determine whether TBX3 and/or CAPERα interact with, recruit, or modify the function of EZH2, SUV39 and other methyltransferases will be informative.

Previous studies showed that TBX3 represses transcription of *p14*^*ARF*^ (upstream of p53) ([@bib3]; [@bib20]; [@bib43]), yet embryonic lethality and mammary phenotypes of *Tbx3* mutants are p53-independent ([@bib39]). Our findings reconcile these observations because CAPERα/TBX3 represses *p16*^*INK*^, the p16/RB pathway is activated in *Tbx3−/−* embryos, and knockdown of either RB or p16 (but not p53) prevents senescence after loss of CAPERα/TBX3. Furthermore, *Tbx3−/−* and *Cdk2−/−;Cdk4−/−* mutant embryos share multiple phenotypes including RB hypo-phosphorylation, reduced E2F-target gene expression, decreased proliferation and premature senescence of MEFs ([@bib5]; [@bib23], [@bib24]). Our discoveries of multiple CAPERα/TBX3 binding sites across the *CDKN2A* locus, and altered chromatin marks after TBX3 and CAPERα KD, indicate that the complex directly represses transcription by regulating chromatin structure. In total, the data conclusively demonstrate that p16 elevation, *CDK2* and *CDK4* downregulation, and RB hypophosphorylation mediate senescence downstream of CAPERα/TBX3 loss of function in primary human cells and *Tbx3* null mutant embryos. When combined with the pleiotropic effects of CAPERα/TBX3 on *UCA1, DUSP4*, *IL6, HDAC9* and other pathways, it is clear why loss of this repressor induces senescence.

TBX3 may function in nuclear organization and structure: severe changes in nuclear morphology and mislocalization of both CAPERα and laminβ1 are apparent in *Tbx3−/−* MEFs after just one passage, prior to other signs of senescence. Progeria is a rare disease in which *LMNA* mutations induce cellular and organismal senescence in part by altering stoichiometry and interactions of type A and B Lamins. Progeria fibroblasts have decreased expression of *TBX3,* TBX3 interacting proteins, and TBX3 targets ([@bib13]). LMNβ1 is a TBX3 interacting protein ([@bib43]) and expression of *LMNA, LMNβ1,* and *LMNβ2* is disrupted by TBX3/CAPERα KD ([Figure 7---source data 1--3](#SD1-data SD2-data SD3-data){ref-type="supplementary-material"} and [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). TBX3 may regulate *LMN* gene expression and physically interact with Lamins to influence nuclear homeostasis.

There are many downregulated genes common to the senescence responses triggered by RAS^G12V^ and loss of CAPERα/TBX3 however, upregulated transcripts and pathways are largely distinct ([Figure 7N′](#fig7){ref-type="fig"}). This is likely attributable to the presence of direct targets of CAPERα/TBX3 repression in the upregulated data set. It will be informative to determine which Jak-STAT, TLR, and TGFβ pathway members ([Figure 7N](#fig7){ref-type="fig"}) are direct CAPERα/TBX3 targets, as the complex roles of these pathways in the senescence associated secretory phenotype, inducing or enforcing autocrine and paracrine senescence, and tumor progression are emerging ([@bib34]; [@bib59]; [@bib35]; [@bib14]).

Recent discoveries of the pervasive functions of lncRNAs as 'signals, decoys, guides and scaffolds' ([@bib64]), conferred by their ability to interact with other nucleic acids and as protein ligands, has added new layers of complexity to regulation of transcriptional and post-transcriptional gene expression and translation. Although there has been a logarithmic increase in studies exploring lncRNA expression and activity, potential senescence-regulating activities are still largely unexplored. LncRNA *HOTAIR* functions as a scaffold to regulate ubiquitination of Ataxin-1 and Snurportin-1 to prevent premature senescence ([@bib71]). Global alterations in lncRNA expression have been reported in association with replicative senescence ([@bib1]), and telomere-specific lncRNAs that regulate telomere function during this process have been identified ([@bib72]). As this manuscript was in revision, regulation of H4K20 trimethylation of rRNA genes by interaction of quiescence-induced lncRNAs *PAPAS* and Suv4-20h2 was reported ([@bib6]). To our knowledge, *UCA1* is the first lncRNA sufficient to induce senescence.

*UCA1* is expressed in bladder transitional cell carcinomas ([@bib66]) and influences tumorigenic potential of bladder cancer cell lines ([@bib68]; [@bib69]). A very recent study identified hnRNP I as a *UCA1* interacting protein that stabilizes *UCA1* RNA; this interaction was postulated to decrease translation of p27 to support growth of the MCF7 breast cancer line ([@bib33]). In contrast, our results support a tumor suppressor/prosenescence function for *UCA1* in primary cells*. UCA1* increases stability of *p16*^*INK*^ mRNA by sequestering hnRNP A1, employing a decoy mechanism that is in some aspects reminiscent of lncRNA *PANDA* sequestering NF-YA transcription factor to prevent activation of proapoptotic p53 targets and promote cell cycle arrest in the DNA damage response ([@bib64]). In the case of *UCA1* and hnRNP A1 however, the sequestration has a very specific effect: even though *UCA1* expression stabilizes (and hnRNP A1 destabilizes) both *p16*^*INK*^ and *p14*^*ARF*^ mRNAs ([Figure 6A,B](#fig6){ref-type="fig"}), *UCA1* only disrupts the association of hnRNP A1 with *p16*^*INK*^ mRNA ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). In proliferating cells, abundant hnRNP A1 binds with *p16*^*INK*^ mRNA resulting in *p16*^*INK*^ degradation. In senescing cells, *p16*^*INK*^ mRNA levels increase via reinforcing mechanisms of increased transcription and stability: loss of CAPERα/TBX3 activates transcription of *p16*^*INK*^ and *UCA1,* in turn, *UCA1* sequesters hnRNPA1.

We recognize that the systems we employed (primary HFFs, mouse embryos and MEFs), while very informative models, provide limited information directly applicable to aging or tumorigenesis without further experimentation. Our data support an important role for CAPERα/TBX3 in regulation of senescence in developmental contexts and, since the CAPERα/TBX3 complex regulates known critical tumor suppressors and there is an increasing literature supporting roles for both TBX3 and CAPERα in tumor biology, this is another worthy area for future investigation. As noted above, expression of *CDKN2A-p14*^*ARF*^ and *CDKN1A*-*p21*^*CIP*^ are repressed by TBX2 and TBX3 and this is postulated to confer the ability of overexpressed TBX2 and TBX3 to permit senescence bypass of *Bmi1*−/− and SV40 transformed mouse embryonic fibroblasts, respectively ([@bib38]; [@bib8]; [@bib56]). Numerous overexpression studies have suggested a role for TBX3 in breast cancer (([@bib47]) and references therein) and recent papers have reported the tumorigenic and proinvasive effects of overexpressed TBX3 in melanoma cells ([@bib55]; [@bib54]) which may derive in part from TBX3 repression of E-cadherin expression ([@bib57]). More relevant to our work on the importance of the CAPERα/TBX3 complex to prevent senescence and regulate cell proliferation are reports that Tbx3 improves the pluripotency of iPS cells ([@bib26]) and prevents differentiation of mouse ES cells ([@bib37]).

In conclusion, CAPERα/TBX3 acts as a master regulator of cell growth and fate, exerting pleotropic effects by at least two modes of action: (1) regulating chromatin structure and transcription of both coding and non-coding genes and, (2) modulating mRNA stability by altering the association of RNA binding proteins with target transcripts via *UCA1*. Further exploration will identify tissue-specific *UCA1* targets and binding proteins, and determine whether the ability of TBX3 to confer senescence bypass in other contexts requires CAPERα interaction and/or *UCA1* repression. Mining the pathways regulated by *UCA1* and CAPERα/TBX3 will reveal factors that control cell proliferation and fate during development and disease and thus constitute novel cancer therapeutic targets.

Material and methods {#s4}
====================

Mass spectroscopy {#s4-1}
-----------------

Mass spectroscopy as in [@bib43]

Protein extraction and immunoprecipitation {#s4-2}
------------------------------------------

Dignam lysates were prepared and incubated for 4 hr at 4°C with the appropriate antibody followed by 2 hr at 4°C with the pre equilibrated Dynabeads Protein G (Invitrogen). Immune complexes were collected and washed three times with lysis buffer. Pelleted beads were resuspended in 6X Laemmli buffer and subjected to SDS-PAGE analysis followed by immunoblotting with specific antibodies.

Input lanes contain 5% of protein lysate used for IP; the rest was used in the IP and of the IP\'d material, 25% was loaded onto the gel for immunoblotting.

Antibodies {#s4-3}
----------

Tbx3 ([@bib23], [@bib24]), TBX3 (SC-17871,MAB10089,A303-098A), CAPERα (A300-291A), GST (SC-33613), LaminB1 (SC-56144), C-Myc (SC-40), R-IgG (SC-2027), m-IgG (SC-2025), Anti-Flag (Sigma, F3165), H3K9me3 (Cell Signaling, 9754), H3K4me3 (Cell Signaling, 9751), H3K27me3 (Cell Signaling, 9733), H3K9ace (Cell Signaling, 9649), H4K5ace (Cell Signaling, 9672), H3K14ace (Cell Signaling, 4353), p-RB -Ser 810\--811 (SC-16670), p-RB -Ser 795 (SC-7986), p-RB -Ser 780 (SC-12901), Rb1 (SC-73598), H3S10P (SC-8656), H2A K119ub (8240S), p21 (SC-756), p53 (Invitrogen 134100), Cyclin D1 (SC-753), Cyclin D2 (SC-754), Cyclin D3 (SC-755), Cyclin E (SC-20648), CDK2 (SC-6248), CDK4 (SC-601) CDK6 (SC-177), hnRNP K (SC-53620), hnRNP C1/C2 (SC-32308), hnRNP H (SC-10042), hnRNP U (SC-32315), hnRNP A2/B1 (SC-53531), hn RNP A1 (SC-32301), and hnRNP D1 (AB-61193).

MBP pull down assay {#s4-4}
-------------------

Amylose bound MBP and MBP-tagged TBX3 affinity columns were prepared as per the procedure (E8022S, NEB) described in the manufacturer\'s protocol. These beads were incubated with 5 and 10 μg of GST and GST-CAPER at 4°C for 8 hr. Bound proteins were eluted with reduced glutathione and analyzed by Western blotting with anti-CAPER antibody.

Cell transfection {#s4-5}
-----------------

Transfections were performed in HEK293 or EBNA-293 cells with Lipofectamine 2000 (Invitrogen) or in Human fibroblasts with X-tremeGENE HP DNA transfection Reagent (Roche) as per the manufacturer\'s recommendations.

Plasmids {#s4-6}
--------

Wild-type Tbx3 and exon 7 missense, deleted repressor domain (Tbx3ΔRD1), and Tbx3ΔNLS were generated by PCR amplification and cloned into pcDNA3.1. C-terminal deletion constructs Tbx3 1-655, Tbx3 1-623, Tbx3 1-565, Tbx3 1-470 were generated by PCR amplification and cloned into pCS2 with an N-terminal Myc tag. Tbx3 L143P and N277D point mutants were kind gifts of Phil Barnett. *UCA1* and CAPERα cDNAs were cloned into pCDN3.1 and PQCXIH for over- expression studies, respectively. Sequence of all plasmids was confirmed. Tbx3 L143P and N277D point mutants plasmids were kind gifts of Phil Barnett. Wild-type CAPERα was generated by PCR amplification and then cloned into pQCXIH retroviral vector; sequence was confirmed. Full length *UCA1* was amplified by PCR and then cloned into pcDNA3.1 vector; sequence was confirmed.UCA1 Cloning FP: AGTTGCGGCCGCTGACATTCTTCTGGACAATGAGUCA1 Cloning RP: TCCTGCGGCCGCTTGGCATATTAGCTTTAATGTAGCAPERα Cloning FP: CATCGCGGCCGCATGGCAGACGATATTGATATTGCAPERα Cloning RP: ACGTGGATCCTCATCGTCTACTTGGAACCAGTAG

Immunofluroscence {#s4-7}
-----------------

E10.5 embryos were harvested in PBS followed by overnight fixation at 4°C in 4% paraformaldehyde and processed for 7 μm cryosections. For cell lines, human fibroblasts were cultured on 8-well chamber slides (BD Flacon) and processed for Immunohistochemistry. Immunohistochemistry was performed using primary antibodies listed above and detected using donkey anti-goat or anti-rabbit Alexa fluor 594 (1:500) and goat anti-mouse Alexa fluor 488(1:500) from Invitrogen. Nuclei were stained with Hoechst or DAPI. Slides were imaged with a Nikon ARI inverted confocal microscope at the University of Utah Imaging Core.

Retroviral transduction and selection of stable cells {#s4-8}
-----------------------------------------------------

shRNA oligonucleotides (see sequences below) were annealed and cloned into the pGFP-B-RS, pRFP-C-RS (Origen) vector and PMK0.1 vector. shRNA against luciferase served as a negative control. High-titer retrovirus was produced by transfection of shRNA retroviral construct along with gag/pol and VSVG encoding plasmids into EBNA-293 cells by lipofectamine 2000 reagent as per the manufacturer\'s protocol. Virus containing supernatant was collected after 48 hr of transfection and filtered through 0.45-μM filters (Fisher 09-720-4). HEK293 or HFFs were incubated with DMEM containing polybrene (8 mM) and 500 μl of TBX3 or CAPERα shRNA encoding retrovirus. 24 hr post infection, cells were split to lower densities and blasticidin or puromycin antibiotic selection applied for 2 days. Stably integrated colonies were selected and analyzed for knock down efficiency by western analysis using Tbx3 or CAPERα antibody.TBX3 shRNA A: targets *TBX3* exon 7TBX3 shA FP: CCGG GACCATGGAGCCCGAAGAA ttcaagaga TTCTTCGGGCTCCATGGTC TTTTTGTBX3 shA RP: AATTCAAAAA GACCATGGAGCCCGAAGAA tctcttgaa TTCTTCGGGCTCCATGGTCTBX3 shRNA B: targets *TBX3* exon 5TBX3 shB FP: CCGG CAGCTCACCCTGCAGTCCA ttcaagaga TGGACTGCAGGGTGAGCTG TTTTTGTBX3 shB RP: AATTCAAAAA CAGCTCACCCTGCAGTCCA tctcttgaa TGGACTGCAGGGTGAGCTGCAPERα shRNA A: targets *CAPERα* (gene name *RBM39*) exon 5CAPERα shA FP: CCGG GACAGAAATTCAAGACGTTttcaagagaAACGTCTTGAATTTCTGTCTTTTTGCAPER shA RP: AATTCAAAAA GACAGAAATTCAAGACGTT tctcttgaa AACGTCTTGAATTTCTGTCCAPERα shRNA B: targets *CAPERα* exon 1CAPER shB P:CCGG AAAGCAAGAGCAGAAGTCGTAttcaagagaTACGACTTCTGCTCTTGCTTT TTTTTGCAPER shB RP: AATTCAAAAA AAAGCAAGAGCAGAAGTCGTA tctcttgaa TACGACTTCTGCTCTTGCTTT

The pMKo.1 puro RB and pMKo.1 puro p53 shRNA vectors were a kind gift of William Hahn obtained via Addgene.pRB shRNA: Addgene \#10670p53 shRNA: Addgene \#10672p16 shRNA: Addgene \#22271

Efficacy and specificity of the pRb, p53, and p16 shRNAs was validated with second shRNAs, and these reagents have been used extensively by many investigators in the years since their initial publication ([@bib50]; [@bib62]; [@bib7]; [@bib25]; [@bib29]; [@bib19]).*UCA1* shRNA: targets *UCA1* exon 3UCA1 shA FP: GATCCGTTAATCCAGGAGACAAAGAtcaagagTCTTTGTCTCCTGGATTAACTTTTTTGGA*UCA1* shA RP: AGCTTCCAAAAAAGTTAATCCAGGAGACAAAGActcttgaTCTTTGTCTCCTGGATTAACGSenescence associated β-galactosidase assayPerformed as per the manufacturer\'s protocol (9860, Cell Signaling).Population doubling assay/3T5 growth curves ([Figure 2E,F,R](#fig2){ref-type="fig"})

Primary HFFs were plated in a 10-cm dish and transduced with retrovirus. After 24 hr, cells were cultured with antibiotic selection (puromycin or blasticidin) for an additional 24--72 hr. On day 0 of the 3T5 growth curve, cells were trypsinized, counted and 500,000 cells were then plated per 10-cm dish. This procedure was repeated every 3 days for 15 days. Population doublings were calculated by (logN1/log2) − (logN0/log2) N1 = current cell count, N0 = Initial cell count. Curves shown in [Figure 2](#fig2){ref-type="fig"} are representative of two independent experiments.

Cell count ([Figure 5C](#fig5){ref-type="fig"}) {#s4-9}
-----------------------------------------------

Primary HFFs were plated in 6-well dishes and transfected at 70% confluence. At days noted in the figure, cells were trypsinized and counted using a hemocytometer.

Crystal violet assay/optical density method of cell quantitation {#s4-10}
----------------------------------------------------------------

5 × 10^5^ cells were plated per well in 6-well tissue culture plates. At times indicated, medium was removed and cells were washed with PBS, and fixed for 10 min in 10% formalin solution. Cells were rinsed 5X with distilled water, and then stained with 100 μl 0.1% crystal violet solution for 30 min, rinsed 5X in water and dried. Cell-associated crystal violet dye was extracted with 500 μl of 10% acetic acid. Aliquots were collected and optical density at 590 nm measured. Each point on the curve shown represents three independent plates.

Senescence marker gene expression in TBX3 and CAPERα KD fibroblasts {#s4-11}
-------------------------------------------------------------------

Primary HFFs were incubated with TBX3 or CAPERα or Control shRNA encoding retrovirus medium with fresh virus added every 8 hr for 48 hr, followed by antibiotic selection for 6 days. 6 days after selection, floating cells were discarded and adherent cells were utilized for senescence associated β-gal assay or preparation of RNA.

RNA isolation and reverse transcription-PCR analysis {#s4-12}
----------------------------------------------------

Total RNA was prepared using the RNeasy RNA isolation kit (Qiagen) or NucleoSpin RNA II Kit (Clontech) and cDNA was synthesized by cDNA EcoDry Premix Double Primed (Clontech) kit. Q-RT-PCR was performed with SoFast Evagreen Supermix (Bio-Rad) as per manufacturer\'s protocol.

RT-PCR primer sequences {#s4-13}
-----------------------

TBX3: TGAGGCCTTTGAAGACCATG, TCAGCAGCTATAATGTCCATCCAPERα: CGGAACAGGCGTTTAGAGAA, TGGCACTGCTCAACTTGTTCCDK2: GCTTTCTGCCATTCTCATCG, GTCCCCAGAGTCCGAAAGATCDK4: ACGGGTGTAAGTGCCATCTG, TGGTGTCGGTGCCTATGGGAP21: TCAGAGGAGGCGCCATGT, TGTCCACTGGGCCGAAGACDC2: GGGGATTCAGAAATTGATCA, TGTCAGAAAGCTACATCTTCMDM2: ACCTCACAGATTCCAGCTTCG, TTTCATAGTATAAGTGTCTTTTTMAPK14: TTCTGTTGATCCCACTTCACTGT, ACACACATGCACACACACTAACCDKN2C: CAATGGCTCAGTTTTGCTGAATAA, GTAAGATCTGCCTGCCAAAAGCCDKN2B: AACGGAGTCAACCGTTTCGG, TGTGCGCAGGTACCCTGCAP16: CAACGCACCGAATAGTTACG, AGCACCACCAGCGTGTCSerpinE1:CCGGAACAGCCTGAAGAAGTG, GTGTTTCAGCAGGTGGCGCP14ARF: CCCTCGTGCTGATGCTACTG, ACCTGGTCTTCTAGGAAGCGGMCM3: CCTTTCCCTCCAGCTCTGTC, CTCCTGGATGGTGATGGTCTTGFb: AAGGACCTCGGCTGGAAGTG, CCCGGGTTATGCTGGTTGTAEGR1: CCAGGAGCGATGAACGCAAGCGGCATACCAAG, GGAGTACGTGGTGGCCACCGACGGGGACCCE2F1: ATGTTTTCCTGTGCCCTGAG, ATCTGTGGTGAGGGATGAGGE2F2: GGCCAAGAACAACATCCAGT, TGTCCTCAGTCAGGTGCTTGIL6R: CATTGCCATTGTTCTGAGGTTC, AGTAGTCTGTATTGCTGATGTCGSK3b: ACTCCACCGGAGGCAATTG, GCACAAGCTTCCAGTGGTGTTUCA1:GAAATGGACAACAGTACACGCATATGGGGC, CCTGTTGCTAAGCCGATGATACATTACCCTHPRT: GCTGGTGAAAAGGACCTCT, CACAGGACTAGAACACCTGCPCNA: AAGAGAGTGGAGTGGCTTTTG, TGTCGATAAAGAGGAGGAAGCCHK2: CTTATGTGGAACCCCCACCTAC, CAGCACGGTTATACCCAGCAPMAIP1: GTTTTTGCCGAAGATTACCG, CAATGTGCTGAGTTGGCACTMYC: CTCCCTCCACTCGGAAGGA, GCATTTTCGGTTGTTGCTGATCDKN2D: CAACCGCTTCGGCAAGAC, CAGGGTGTCCAGGAATCCAP53: CCTCACCATCATCACACTGG, TCTGAGTCAGGCCCTTCTGTRB: TGTGAACATCGAATCATGGAA, TCAGTTGGTGGTTCTCGGTCCXCL10: GAAATTATTCCTGCAAGCCAATTT, TCACCCTTCTTTTTCATGTAGCAIFNB1: GAATGGGAGGCTTGAATACTGCCT, TAGCAAAGATGTTCTGGAGCATCTCATF3: GTTTGAGGATTTTGCTAACCTGAC, AGCTGCAATCTTATTTCTTTCTCGTDUSP2: GGCCTTTGACTTCGTTAAGC, CCACCTCAGTGACACAGCACCREB5: CGTGCCTCCTTGAAACAAGCCATT, ATGAAACACCAGCACCTGCCTAGAHDAC9: AGTGTGAGACGCAGACGCTTAG, TTTGCTGTCGCATTTGTTCTTTSP140: TGGGTCAGTTTCTTGTTTATCTGC, AGCAGGCTAGAAGCAAGCTCEGR2: TTGGTGCCTTGTGTGATGTAGAC, CTTTCCATAAGGCAACCCATTTHMGA2: GTCCCTCTAAAGCAGCTCAAAA, CTCCCTTCAAAAGATCCAACTGBIRC5: CATGGTAGGTGCAGGTGATG, CATGGTAGGTGCAGGTGATGASF1: GGTTCGAGATCAGCTTCGAG, CATGGTAGGTGCAGGTGATGWDR66: CCGAGAAGCAACAGGAGAAA, CTGTGTCTCCAAACGGATCACDC25C: GACACCCAGAAGAGAATAATCATC, CGACACCTCAGCAACTCAGCENPF: CGAAGAACAACCATGGCAACTCG, TTCTCGGAGGATGGTGCCTGAATLAMA2: AATTTACCTCCGCTCGCTAT, CCTCCAATGTACTTTCCACGLMNB1: AAGCAGCTGGAGTGGTTGTT, TTGGATGCTCTTGGGGTTCLMNB2: GCTCTGACCAGAACGACAAGG, CCAGCATCTTCCGGAACTTGCDC20: TCCAAGGTTCAGACCACTCC, GATCCAGGCCACAGACCATADUSP5: GCTCGCTCAACGTCAACCTCAACTCGGTG, AGTGGCGGCTGCCCTGGTCCAGCACCACCDUSP4: CCTGGCAGCCATCCCACCCCCGGTTCCCC, GCTGATGCCCAGGGCGTCCAGCATGTCTCTCmTbx3: TGAGGCCTCTGAAGACCATG, TCAGCAGCTATAATGTCCATCmSerpinE1: AGCCAACAAGAGCCAATCAC, GGATTCTCGGAGGGGTAAAGmIL6: GATGGATGCTACCAAACTGGA, CCAGGTAGCTATGGTACTCCAGAAmP21: TCCACAGCGATATCCAGACA, GGCACACTTTGCTCCTGTGmCdc2: CTGCAATTCGGGAAATCTCT, TCCATGGACAGGAACTCAAAmReprimo: CTTACGGACCTGGGACTTTG, CCAGCACTGAATTCATCACG

MEF isolation from WT and *Tbx3* null embryos {#s4-14}
---------------------------------------------

All steps were performed under aseptic conditions. Pregnant female mice were euthanized and 13.5-day-old embryos were isolated from the uterus. Embryos were washed in sterile PBS in 60-mm tissue culture dish at room temperature and transferred into 15-ml sterile falcon tube containing 1 ml of 50% trypsin in DMEM medium. Embryos were minced using fine scissors followed by gentle pipetting with 1 ml pipette tips and dispersed into cell suspensions in 5 min. Suspensions were plated into 10-cm plates in 10 ml of DMEM with 5% FBS and penicillin/streptomycin and incubated for 8 hr in CO~2~ incubator. Culture medium was replaced with fresh medium every day for 3 days. Passage 0 refers to the stage when cell suspension from the embryos was put into cell culture and subsequent passages are numbered.

Chromatin immunoprecipitation (ChIP) {#s4-15}
------------------------------------

Performed as per the manufacturer\'s protocol (9003S, Cell Signaling).

### ChIP primers {#s4-15-1}

UCA1 FP1: GGCTCTCGAGTCAAGATAATTCACTTACUCA1 RP1: GGCACATCTTTGTTGTCTGAAAGGGATUCA1 FP2: CACCTCTTTCTTGCCTCCTTGGATATATTUCA1 RP2: CACTTACTTACTTATAATAGAGTCAGGGTCTUCA1 FP3: CCAGGAGCTGATATTCATGACCCTCCAUCA1 RP3: CTTGGCTCCTGTAGGCCACCTGGACATDUSP4 FP: CGAGGGCACCGGTACCCGCCGGGTCTCTCCDUSP4 RP: GGACTAGGGTGAGCACAAGCCTTGAGCGCP16 1A FP: CGACCGTAACTATTCGGTGCGTTGGGCAGCP16 1A RP: GCTCTGGCGAGGGCTGCTTCCGGCTGGTGCP16 2A FP: GAGCAGGACGCGGTGGCTCACACCTGTAATP16 2A RP: CAGGCATGCGCCACCAAGCCCCGCTAATTP16 3A FP: CCTCGGGGTACCTCTCAATTAGCTGTGTAP16 3A RP: AGTTCGAGACAAGCCTAGCCAACATAGTGP16 4A FP: GAAACTCTACCATGGATTCCTACATCAAGP16 4A RP: GCACAATGTGCAGGTTTGTTACATATGTATP16 5A FP: CCAGTCTCAGATTTCCTATGTGCAAAATGP16 5A RP: GGTTTGAACCCTGGCAGTCTGACTGTAGP16 6A FP: GCGGTGGTTATAGATTTTGTCACAAGAGP16 6A RP: ACTCTGGAACACTACCTTCTCAAGTATCP16 7A FP: ACCCCGATTCAATTTGGCAGP16 7A RP: AAAAAGAAATCCGCCCCCGP14ARF: FP: GCCGAATCCGGAGGGTCACCAAGAACCTGCP14ARF: RP: GTGCGCAGGGCTCAGAGCCGTTCCGAGATCTCDK2 FP: GATGGAACGCAGTATACCTCTCCDK2 RP: AAAGCAGGTACTTGGGAAGAGTGCDK4 FP: GTGGACCGAAAAGGTGACAGGATCCDK4 RP: GGGCGGGGCGAACGCCGGACGTTCP21 −324 to −676 FP: CCCGGAAGCATGTGACAATCP21 −324 to −676 RP: CAGCACTGTTAGAATGAGCCP21 −677 to −981 FP: GGAGGCAAAAGTCCTGTGTTCP21 −677 to −981 RP: GGAAGGAGGGAATTGGAGAGP21 −964 to −1340 FP: CTGAGCAGCCTGAGATGTCAGP21 −964 to −1340 RP: CACAGGACTTTTGCCTCCTGP21 −1335 to −1688 FP: GAAATGCCTGAAAGCAGAGGP21 −1335 to −1688 RP: GCTCAGAGTCTGGAAATCTCCDKN1B FP: CGGCCGTTTGGCTAGTTTGTTTGTCDKN1B RP: GGAGGCTGACGAAGAAGAAGATGAHDAC9CHIPFP: GGCTCAGGCCGACCATTGTTCTATTTCTGTHDAC9CHIPRP: CCTGAGGAGAAGCAGCAGAGGATCAACIL6CHIPFP: GAACCAAGTGGGCTTCAGTAATTTCAGGIL6CHIPRP: CATCTGAGTTCTTCTGTGTTCTGGCTCTCP14ARF FP: CCCTCGTGCTGATGCTACTGP14ARF RP: ACCTGGTCTTCTAGGAAGCGGTGFB1 FP: GATGGCACAGTGGTCAAGAGCTGFB1 RP: GAAGGATGGAAGGGTCAGGAGRB FP: GGCGGAAGTGACGTTTTCRB RP: CCGACTCCCGTTACAAAAATMYC FP: AAGATCCTCTCTCGCTAATCTCCMYC RP: AGAAGCCCTGCCCTTCTCE2F1 FP: GGCTACAGGTGAGGGTCACGE2F1 RP: GAGCGCCGCCACAATTGGCTCDKN2D FP: TCCCTTTCTTCACGGTGCTTCDKN2D RP: GCGTCGCTCCTGATTGGTCCDK2 FP : AAGCAGGTACTTGGGAAGAGTGTTCAGCCDK2 RP: CAACTTGAAACAATGTTGCCGCCTCCMDM2 FP: GGCCTACCCAAAGTGATGGGATTACAAGMDM2 RP: GCCGCTGGAGTTGTACCCAAATGAGTTA

siRNA knockdown {#s4-16}
---------------

For differential display ([Figure 4](#fig4){ref-type="fig"}), HEK293 cells were transfected with control siRNAs (Sense; 5′-CAGCGACUAAACACAUCA-3′ Antisense; 5′-UUGAUGUGUUUAGUCGCUGTT-3′) or TBX3 specific siRNA A (Sense: GACCAUGGAGCCCGAAGAA, Antisense: UUCUUCGGGCUCCAUGGU) or CAPERα-specific siRNA (Sense: GACAGAAAUUCAAGACGUU, Antisense: AACGUCUUGAAUUUCUGUC) using lipofectamine 2000 (Invitrogen) or X-treme GENE HP DNA transfection reagent as per manufacturer\'s instructions.

HNRNP A1 siRNA for knockdown in HFFs ([Figure 6](#fig6){ref-type="fig"}) was obtained from Cell Signaling (cat. \#7668).

Oncogene-induced senescence with constituitively active RAS {#s4-17}
-----------------------------------------------------------

^V12G^RAS virus was produced with pBABE-^V12G^RAS as per the procedure described above. HFFs were transduced with RAS virus and incubated with antibiotic selection medium (puromycin 2 μg/ml) for 4--5 days.

RNA immunoprecipitation (RIP) and RIP-PCR {#s4-18}
-----------------------------------------

For RNA immunoprecipitation, 10 million cells were lysed in 1 ml of NP-40 lysis buffer (50 mM Tris HCl, ph7.4, 150 mM NaCl, 1% NP-40 and Protease inhibitor cocktail). Lysate was cleared by centrifugation at 12,000 RCF for 15 min. Cleared lysate was immunoprecipitated independently with 5 μg of anti-hnRNP A1, anti-hnRNP D, Anti-hnRNP A2/B1, Anti-hnRNP C1/C2, Anti-hnRNP K, mIgG and R-IgG antibodies. Immune complexes were incubated with 30 μl of pre-equilibrated Dynabeads for 4 hr at 4°C. Dynabead purified immune complexes were subjected to Proteinase K digestion at 37°C for 1 hr followed by NucleoSpin RNA II purification kit and cDNA was prepared by RNA-to-cDNA EcoDry Premix kit (Clontech). cDNA was used as a template in PCR amplifications with gene specific primers.

mRNA stability assays {#s4-19}
---------------------

TBX3, CAPERα, or Control shRNA KD, PS and RAS HFFs were cultured in 6-well culture dishes for 2 days to 80% confluence. Then Actinomycin D was added to a final concentration of 5 mg/ml to suppress transcription. At 0, 1, 2, and 4 hr after addition of Actinomycin D, equal numbers of cells were harvested from each sample and mRNA was prepared by nucleoSpin RNA II purification kit and cDNA was prepared by RNA-to-cDNA EcoDry Premix kit (Clontech) followed by qRT-PCR for specific transcripts.

P16^INK^ mRNA northern blot {#s4-20}
---------------------------

HFFs were transfected with pcDNA3.1 control or *UCA1* expression plasmids as described above, incubated +/− Actinomycin D, and total cellular RNA was harvested at 0, 1, 2, and 4 hr post treatment. For northern blot analysis, 5 µg total RNA from each time point was electrophoresed through a 1% agarose gel. The RNA was blotted onto Hybond-N+ membrane (Amersham Pharmacia), and membranes were UV crosslinked. Membranes were hybridized for 18 hr with ([@bib63]) P-labeled probes. Probes were generated by end-labeling DNA oligonucleotides containing following sequences complementary to *p16*^*INK*^ mRNA:5′ GAGGAGGTGCTATTAACTCCGAGCATTAGCGAATGTGGC5′ AATCCTCTGGAGGGACCGCGGTATCTTTCCAGGCAAGGGG5′AAGGCTCCATGCTGCTCCCCGCCGCCGGCTCCATGCTGCT

End-labeling reactions were performed using T4 polynucleotide Kinase (NEB) according to the manufacturer\'s directions. The hybridized blots were washed, and autoradiographs were developed as per standard procedure. Band intensities were measured by Image J analysis, and densitometric vales were plotted as bar graphs.

RNA-Seq analysis of TBX3 and CAPERα KD HFFs {#s4-21}
-------------------------------------------

HFFs were incubated with TBX3 or CAPER α shRNA encoding retrovirus for 48 hr followed by incubation for an additional 48 hr in selection medium. Total RNA was isolated and purity was assessed. Poly-A RNA was purified, fragmented, primed with random hexamers and used to generate first strand cDNA using reverse transcriptase. Samples that passed quality control steps were used for Illumina library preparation using the Illumina TruSeq RNA Sample Prep protocol. All libraries were sequenced (with barcoding) on a single lane of an Illumina HiSeq instrument for 50 cycles from a single end. A total of 177,155,781 reads were produced in total for all 10 libraries (median 17,348,374 reads). Base calling was performed using Illumina software.

Bioinformatics analysis {#s4-22}
-----------------------

Sequence reads were aligned (98.5% mapped) to the human genome build 37.2 with Tophat (v2.0.8b) using default parameters. Aligned reads were assembled into transcripts and their relative abundance was measured using Cufflinks (v2.1.1) with fragment bias correction (frag-bias-correct) and multi-read correction (multi-read-correct). Cufflinks transcript assemblies were based on transcripts of NCBI Homo sapiens annotation release 104 and miRBase release 19 as provided in the Illumina iGenomes data set. Cuffdiff was used to test for differential expression between samples and controls and expression differences were taken as significant if the FDR adjusted p-value was less than 0.05 (Source Data Files 1 and 2). Statistically overrepresented gene ontology/biologic process categories and KEGG pathways were determined using DAVID ([@bib32], [@bib31]). The hypergeometric test, as implemented in the R statistical language (phyper), was used to test significance of the number of genes found to be co-regulated between samples ([Figure 7---source data 3](#SD3-data){ref-type="supplementary-material"}).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Coordinated control of senescence by lncRNA *UCA1* and a novel CAPERα/TBX3 co-repressor" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 2 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewer discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

In this study, Kumar et al. report on the role of corepressor complex composed of Caper and TBX3 in control of senescence. They document the existence of a Caper-TBX3 complex and then show that it is required to prevent senescence. They go on to demonstrate that the Caper-Tbx3 functions to prevent senescence by repression of p16 and RB family members. Most interestingly, they show that Caper-Tbx3 targets and repress a long non-coding RNA, UCA1, and that over-expression of UCA1 is sufficient to induce senescence. They provide evidence that p16 mRNA is bound and destabilized by hnRNP A1 and that UCA1 stabilizes p16 mRNA by sequestering hnRNP A1. Activated Ras, which induces senescence in primary cells, disrupts and inactivates the Caper-TBX3 corepressor resulting in UCA1 expression and senescence induction.

In general, the major conclusions of the work are interesting and supported by the presented results. However, there are number of areas in which the manuscript can be improved.

The following issues must be addressed for publication in *eLife*.

1\) It is relatively standard in shRNA experiments to validate the results using a second shRNA against the same target gene to rule out off-target effects. Ideally, two shRNAs should be used for all experiments but minimally this should be done for the initial and key experiments. Two shRNAs to Caper and Tbx3 are mentioned in the methods section but it is not clear which were used in the various experiments and whether any experiment was performed with two shRNAs. This same concern applies to the other shRNAs used in the study, such as that directed against p53.

2\) In the knockdown/ectopic expression rescue experiments, it is not clear whether the ectopically expressed mRNA is subject to RNAi-mediated degradation. This can affect the interpretation of the results.

For example, in the experiments performed to determine the domain of TBX3 required for interaction with CAPERalpha. Use of shRNAs against TBX3 makes the interpretation of the results difficult, because it might also target some of the TBX3 deletion constructs. It would be preferable to perform these experiments using epitope-tagged TBX3 in the absence of shRNAs against TBX3.

Also, the rescue experiments using ectopic expression of CAPERalpha are difficult to interpret without knowing the region of CAPERalpha mRNA that is being targeted by the CAPERalpha shRNA. Please provide this information for all the shRNAs in the experimental methodology section. As in point 1 above, the authors should also include a second shRNA for their experiments to rule out shRNA-related "off-target" effects.

3\) Statistical analyses are missing throughout the manuscript. Because of this it is not clear if some of the results presented in the manuscript are statistically significant. Please provide p-values for all of the results.

4\) The reviewers felt that the writing and presentation of the manuscript can be considerably improved. For example, there are uncommon usage of phrases (for example, embryonic mice, rather than mouse embryo; oncogene-induced stress physically dissociate, rather than disrupt; many others).

In general the figure legends are too sparse for the interested reader to fully understand how the experiments were carried out and presented. *eLife* does not have arbitrary word limits so there is no reason that additional details can\'t be provided. For example, in the mass spec experiment of [Figure 1A](#fig1){ref-type="fig"}, it is not clear which peaks are those of Caper and there is no information in the legends. In [Figures 1b, c](#fig1){ref-type="fig"} and elsewhere there is no description as to what the black and red arrows indicate.

Finally, in the Method section, I could find no description of the methods used for the RIP experiments.

The following issues would be desirable to address for publication in *eLife*. We encourage the authors to address as many of these as possible.

1\) The experiments in [Figures 1](#fig1){ref-type="fig"} E-G seem very tangential to the main conclusions of this study. The authors should consider removing these to help focus the manuscript.

2\) For all of the mRNA stability experiments can the authors provide a half-life estimate for the mRNA and discuss whether the half-life measurement is consistent with those obtained in other studies. Also, it would be desirable to confirm at least the key half-life experiments, such as those measuring p16 mRNA, by northern blot to rule out possible amplification artifacts that can arise by PCR.

3\) [Figure 6D](#fig6){ref-type="fig"}. Can the increased hnRNPA1 binding to UAC1 following Ras expression be attributed to increased UAC1 RNA levels?

4\) Why is H3K27me3 levels measured in some but not all experiments?

5\) [Figure 7](#fig7){ref-type="fig"}. In contrast to what is stated in the text, it is not clear that Caper levels markedly decrease in the cytoplasm. Also in panels J and L the magnifications are not equivalent.

6\) The authors use differential display to identify UAC1. This is an older and currently infrequently used procedure. Can the authors provide a rationale for their use of differential display?

7\) The authors show that CAPERalpha/TBX3 regulates histone modifications associated with p16 and UCA1 promoters. However, it is not clear how CAPERalpha/TBX3 achieves this. Are the changes in histone modifications a direct consequence of CAPERalpha/TBX3 activity? It would be desirable if the authors had results that address this issue but minimally the various possibilities should be discussed. Additionally, it would be desirable for these experiments if total RNA polymerase II and elongating RNA polymerase II ChIP results could be included.

8\) The results describing the role of CAPERalpha/TBX3 in premature senescence and oncogene-induced senescence are interesting but do not provide any insight into the role of this CAPERalpha/TBX3 pathway in either the process of aging or RAS-driven tumor initiation. Is there a tumor type where the authors can show this regulation occurs and modulates RAS-induced tumor initiation? This would add an important physiological context. Fibroblast-based experiments do not provide meaningful advances in our understanding for the role of CAPERalpha/TBX3 mediated senescence repression to either aging or tumorigenesis. Also, it will be desirable to determine the state of telomerase expression/activity, telomere length and state of shelterin proteins in the experiments where premature senescence is measured.

9\) There are several previous reports that TBX3 represses cellular senescence. These previous should be discussed. Similarly, there are several reports on the role of long non-coding RNAs in the regulation of cellular senescence and these studies should also be discussed.
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Author response

1*) It is relatively standard in shRNA experiments to validate the results using a second shRNA against the same target gene to rule out off-target effects. Ideally, two shRNAs should be used for all experiments but minimally this should be done for the initial and key experiments. Two shRNAs to Caper and Tbx3 are mentioned in the methods section but it is not clear which were used in the various experiments and whether any experiment was performed with two shRNAs. This same concern applies to the other shRNAs used in the study, such as that directed against p53*.

For clarity, we have now separated the data on effectiveness and specificity of the CAPERα and TBX3 shRNAs (two different shRNAs for each) and they are now presented in [Figure 2--figure supplements 1 and 2](#fig2s1 fig2s2){ref-type="fig"}, respectively. The two different shRNAs have comparable effects on SAβgal activity; in both cases, subsequent experiments were performed with TBX3 shRNA A and CAPERα shRNA A and information as to their target sites within the mRNAs is now provided in the Methods.

The p53, p16 and pRb shRNAs we used were obtained from Addgene (please see Methods for specific information); their efficacy and specificity has been validated against second shRNAs and these reagents have been used extensively by many investigators in the years since their initial publication including (but not limited to) \[1-5\]. We have now cited the original use of these reagents in the Results section and the Methods of the revised manuscript.

*2) In the knockdown/ectopic expression rescue experiments, it is not clear whether the ectopically expressed mRNA is subject to RNAi-mediated degradation. This can affect the interpretation of the results*.

We completely agree that this is an important consideration and apologize that our strategies to deal with this issue were not made clear.

In our manuscript that was in press at the time of the original submission and is now published \[6\], we show that all the mutant Tbx3 (mouse) proteins are produced in TBX3 knockdown HEK293 cells ([Figure S2](#fig2){ref-type="fig"} of the published manuscript). We apologize that we did not provide access to this data to the reviewers of the present manuscript and have remedied this by citing the paper, extensively revising the text, legend, and figure in the revised manuscript to more clearly explain the experimental design.

The DNA binding domain mutants and the ΔRD and exon7 missense mutations are untagged while the C-terminal deletion mutants are Myc-tagged. In order to assay the interactions of the untagged proteins with CAPERα, we needed to use TBX3 shRNA knockdown HEK293 cells. [Figure 1](#fig1){ref-type="fig"}, panel J shows that CAPERαis present and can be IP'd despite knockdown of endogenous human TBX3 and subsequent overexpression of mutant mouse Tbx3 proteins. Panel J' shows that the Tbx3 point mutant proteins (L143P, N227D) coIP with CAPERα in an anti-CAPERα IP. We did not think it necessary to show that the mutant proteins were expressed in the knockdown cells since they are detected in the IP with CAPERαand the data demonstrating their production in the knockdown cells are published.

The deletion constructs were Myc- tagged and did not require assay in knockdown cells and so panels K/K' are in wild type HEK293 cells. Thus, failure to detect interaction is not attributable to knockdown of the overexpression mutant mRNAs. In this case, because the IP was performed for Myc-Tbx3, panel K shows that the Myc-tagged deletion mutants can be IP'd by the anti-Myc antibody. In Panel K', probing the anti-Myc IP for CAPERα shows that deletions more proximal than amino acid 655 disrupt the CAPERα/Tbx3 interaction.

The observation that C-terminal deletions interfere with CAPERα/Tbx3 led us to test whether the C-terminal repressor domain was important for the interaction (K, K'). In this case, because there was no interaction of the untagged ΔRD mutant with CAPERα, we thought it important to show that both the control and ΔRD mutant proteins were produced in the knockdown cells even though this has now been published.

In addition to revising the text and legend, we have modified the figure to illustrate which proteins are tagged and untagged in the schematic.

All the data are consistent with the conclusion that the C-terminal portion of Tbx3 and the C-terminal repressor domain are required for interaction with CAPERα.

*For example, in the experiments performed to determine the domain of TBX3 required for interaction with CAPERalpha. Use of shRNAs against TBX3 makes the interpretation of the results difficult, because it might also target some of the TBX3 deletion constructs. It would be preferable to perform these experiments using epitope-tagged TBX3 in the absence of shRNAs against TBX3*.

*Also, the rescue experiments using ectopic expression of CAPERalpha are difficult to interpret without knowing the region of CAPERalpha mRNA that is being targeted by the CAPERalpha shRNA. Please provide this information for all the shRNAs in the experimental methodology section. As in point 1 above, the authors should also include a second shRNA for their experiments to rule out shRNA-related "off-target" effects*.

These sequences were originally listed in the methods section but not specifically labeled as to which were employed, we have now clarified this and also state the region of the mRNA that is targeted by each shRNA in the Methods section.

*3) Statistical analyses are missing throughout the manuscript. Because of this it is not clear if some of the results presented in the manuscript are statistically significant. Please provide p-values for all of the results*.

We have now added p values for all data as requested. As is standard for the presentation of qPCR gene expression data, the data is presented in bar graph form with the mean and standard deviation represented as error bars. The p values are relative to control levels, as we are not directly comparing transcript levels TBX3 and CAPERα knockdown to one another; the point we are trying to convey with the expression data in [Figure 2O](#fig2){ref-type="fig"} is not that all senescence related genes are dysregulated in a statistically significant manner, but that the overall pattern of change seen in response to loss of TBX3 and CAPERα is similar (as was subsequently confirmed by the transcriptional profiling shown in [Figure 7](#fig7){ref-type="fig"}).

We have further clarified this point in the text.

The 3T5 growth curves shown in [Figure 2 E,F, and R](#fig2){ref-type="fig"} do not have error bars as each point on the population doubling curve represents the total cell count from each plate in an individual experiment. The curves shown are representative of results obtained from 2 independent experiments.

*4) The reviewers felt that the writing and presentation of the manuscript can be considerably improved. For example, there are uncommon usage of phrases (for example, embryonic mice, rather than mouse embryo; oncogene-induced stress physically dissociate, rather than disrupt; many others)*.

We have had the revised manuscript reviewed by additional readers and made edits requested by the reviewers and suggested by the readers.

*In general the figure legends are too sparse for the interested reader to fully understand how the experiments were carried out and presented.* eLife *does not have arbitrary word limits so there is no reason that additional details can\'t be provided. For example, in the mass spec experiment of* [*Figure 1A*](#fig1){ref-type="fig"}*, it is not clear which peaks are those of Caper and there is no information in the legends*.

We have expanded the legend for [Figure 1A](#fig1){ref-type="fig"} as requested; the spectrum fragmentation peaks are diagnostic for one of the six peptides that specifically identified CAPERα. The peptide sequence revealed by the mass spec trace shown is noted on the figure and is: C\*PSIAAAIAAAVNALHGR.

We have also provided additional experimental details in all other figure legends as requested by the reviewers.

*In* [*Figures 1b, c*](#fig1){ref-type="fig"} *and elsewhere there is no description as to what the black and red arrows indicate*.

This information was originally provided at the end of the figure legend, but we have now placed it at the beginning of the legend to alert the reader: "black arrowheads indicate IgG heavy chain and red indicate protein of interest (CAPERα or TBX3)."

*Finally, in the Method section, I could find no description of the methods used for the RIP experiments*.

We apologize for this accidental omission and have now provided the RIP methods.

*The following issues would be desirable to address for publication in* eLife*. We encourage the authors to address as many of these as possible*.

*1) The experiments in* [*Figures 1*](#fig1){ref-type="fig"} *E-G seem very tangential to the main conclusions of this study. The authors should consider removing these to help focus the manuscript*.

We respectfully disagree that the results are tangential as they illustrate key points that led us to pursue the interaction of these two proteins:

a\) Endogenous *Caper*α is very broadly expressed whereas *Tbx3* expression is tissue specific and dynamic. Because we are interested in the developmental implications of this interaction as it may improve our understanding of the mechanisms underlying human ulnar-mammary syndrome associated with mutations in *TBX3*, it was important to determine *in vivo* co-localization in relevant tissues in developing embryos.

b\) Since the data show that the proteins co-localize in the nuclei of some tissue types and not others (particularly apparent when comparing distal limb AER versus mesenchyme), they support the hypothesis that the interaction is regulated and tissue specific.

We have added this rationale to the text to allow the reader to appreciate our logic for these experiments.

*2) For all of the mRNA stability experiments can the authors provide a half-life estimate for the mRNA and discuss whether the half-life measurement is consistent with those obtained in other studies. Also, it would be desirable to confirm at least the key half-life experiments, such as those measuring p16 mRNA, by northern blot to rule out possible amplification artifacts that can arise by PCR*.

To obtain the estimated half-lives, we used linear regression on the data shown in [Figure 6 A and B](#fig6){ref-type="fig"}; those best fit lines, their equations and R values are now shown in [Figure 6--figure supplements 1 and 2](#fig6s1 fig6s2){ref-type="fig"}, respectively. The differences in control half-lives between [Figure 6 A and B](#fig6){ref-type="fig"} are likely attributable to the different control treatments: in A, control cells were transfected with pcDNA3.1 plasmid, while in B, control cells were transfected with control siRNA.

Note that in panel A, *p16*, *p14* and *E2F1* mRNAs do not decay in the time frame examined and their t~1/2~ are denoted as "n" (no decay).

The half-life of an mRNA is cell/context specific (as evident in the differences in control half-lives in A versus B) and in general, cell cycle regulatory genes have short half-lives \[7\]. The t~1/2~ of *p16* mRNA we observed in HFFs transfected with either control plasmid (t~1/2~ ∼3.9) or control siRNA (t~1/2~ ∼2.1) is similar to that reported in HeLa cells (t~1/2~ ∼2.9) \[8\]. The results we obtained were also similar to those reported for *MYC* mRNA \[7, 9\], *CDKN1A* mRNA in HT29-tsp53 cells \[10\] and ES cells \[7\], and *E2F1* mRNA in ES cells \[7\], The half- lives of *Rb* and *TGF*β*1* are mRNAs extremely variable and those we obtained in HFFs were shorter than reported in ES cells \[7\]. We have added this information to the Results section as requested.

We have also provided the p16 Northern blot ([Figure 6--figure supplement 2](#fig6s2){ref-type="fig"}), as requested. The results are consistent with those obtained by qPCR.

*3)* [*Figure 6D*](#fig6){ref-type="fig"}. *Can the increased hnRNPA1 binding to UAC1 following Ras expression be attributed to increased UAC1 RNA levels?*

Exactly: our data indicate that the increase in *UCA1* RNA levels in RAS cells (or after loss of TBX3 or CAPERα) allows *UCA1* to disrupt the *p16* mRNA /hnRNP A1 interaction leading to stabilization of *p16*.

4\) Why is H3K27me3 levels measured in some but not all experiments?

We have added this data as requested.

*5)* [*Figure 7*](#fig7){ref-type="fig"}*. In contrast to what is stated in the text, it is not clear that Caper levels markedly decrease in the cytoplasm*.

We agree and have removed that statement.

*Also in panels J and L the magnifications are not equivalent*.

The panels F-M are at the same magnification: cell and nuclear size of senescing cells is markedly increased (please see scale bar in G and also, [Figure 2--figure supplement 3](#fig2s3){ref-type="fig"} where the same phenomenon occurs in *Tbx3* null MEFs).

*6) The authors use differential display to identify UAC1. This is an older and currently infrequently used procedure*. *Can the authors provide a rationale for their use of differential display?*

We appreciate the reviewers' question: the rationale was that we had no funding for this line of investigation and Dr. Kumar already had the library of differential display primers and experience with this approach so at the time, this was the fastest and cheapest way for us to obtain insight into, and compare, what was happening after loss of TBX3 and CAPERα. Even though we knew it was not a comprehensive analysis, it revealed known and novel senescence effectors and because so little was known about *UCA1*, we pursued it.

*7) The authors show that CAPERalpha/TBX3 regulates histone modifications associated with p16 and UCA1 promoters. However, it is not clear how CAPERalpha/TBX3 achieves this. Are the changes in histone modifications a direct consequence of CAPERalpha/TBX3 activity? It would be desirable if the authors had results that address this issue but minimally the various possibilities should be discussed*.

TBX3 is known to interact directly with HDACs \[11\] but there are no reports of it, or CAPERα interacting with histone methyltransferases or demethylases. Our recently published Mass Spec screen for Tbx3/TBX3 interactors did not identify such factors however, the screen cannot be considered exhaustive as we did not reproducibly detect HDACs or transcription factors thought to interact with Tbx3. Future studies to specifically determine whether TBX3 and/or CAPERα interact with, recruit, or modify the function of EZH2, SUV39 and other methyltransferases will be informative. For the present manuscript, we have added additional discussion regarding known and potential roles for TBX3/CAPERα to regulate histone modifications.

*Additionally, it would be desirable for these experiments if total RNA polymerase II and elongating RNA polymerase II ChIP results could be included*.

We appreciate the reviewers' point, but did not perform these ChIP experiments because we felt that the additional information to be gained was limited since the activating histone modifications observed correlated with the changes in gene expression.

*8) The results describing the role of CAPERalpha/TBX3 in premature senescence and oncogene-induced senescence are interesting but do not provide any insight into the role of this CAPERalpha/TBX3 pathway in either the process of aging or RAS-driven tumor initiation. Is there a tumor type where the authors can show this regulation occurs and modulates RAS-induced tumor initiation? This would add an important physiological context. Fibroblast-based experiments do not provide meaningful advances in our understanding for the role of CAPERalpha/TBX3 mediated senescence repression to either aging or tumorigenesis*.

We agree that the systems we employed (primary HFFs, mouse embryos and MEFs), while informative models, provide limited information that can be directly applied to aging or tumor initiation without extensive further experimentation. Based on the evidence suggesting that TBX3 influences the formation and progression of breast cancer, we performed a very preliminary assay on 8 human breast cancer tissue samples and 2 controls (see [Author response image 1](#fig8){ref-type="fig"}, below). We assayed whether there was a correlation between the ability to detect CAPERα/TBX3 interaction by co-IP and the type of tissue (normal breast, Invasive ductal CA, Ductal Carcinoma in Situ, other carcinoma) or hormone receptor status. We did not observe any correlation however, these data are too preliminary to draw any conclusions because: 1) the sample size was small; 2) we are unable to perform immunohistochemistry on the available samples due to how they were preserved; 3) we do not have the ability to determine how heterogeneous the samples were. For these reasons, we have not included this data in the present manuscript. In the future, we hope to obtain funding for a study to examine CAPERα and TBX3 immunostaining and interaction in a larger clinical sample in which we have more detailed clinical information, and detailed tumor and control histo- and immune- pathology for each patient.Author response image 1.

Despite this uninformative preliminary experiment, our models, and the data derived therefrom, do support an important role for CAPERα and TBX3 in regulation of cell proliferation and senescence in developmental contexts. The role of the p16/RB pathway in tumor initiation is cell and context dependent and thus our observation that CAPERα/TBX3 complex regulates this pathway, combined with an increasing literature supporting roles for both TBX3 and CAPERα in multiple aspects of behavior of different tumor types indicate that several complex lines of investigation focused on specific tumor types will need to be pursued. We have added this to the Discussion.

*Also, it will be desirable to determine the state of telomerase expression/activity, telomere length and state of shelterin proteins in the experiments where premature senescence is measured*.

This manuscript addresses the effects of TBX3/CAPERα and UCA1 on non-telomere dependent mechanisms of senescence induction. Investigating whether TBX3 and/or CAPERα could additionally influence senescence by regulating telomere function is an interesting question, but it is beyond the scope of this paper.

*9) There are several previous reports that TBX3 represses cellular senescence. These previous should be discussed. Similarly, there are several reports on the role of long non-coding RNAs in the regulation of cellular senescence and these studies should also be discussed*.

In the original manuscript, we presented the fact that expression of *CDKN2A-p14*^*ARF*^ and *CDKN1A*-*p21*^*CIP*^ are repressed by TBX2 and TBX3 and that this mechanism has been proposed to account for the ability of overexpressed TBX2 and TBX3 to permit senescence bypass of *Bmi1*-/- and SV40 transformed mouse embryonic fibroblasts, respectively \[12-14\]\_ENREF_7. Numerous overexpression studies have suggested a role for TBX3 in breast cancer initiation and progression (reviewed in \[15, 16\]) and recent papers have reported the tumorigenic and proinvasive effects of overexpressed TBX3 in melanoma cells \[17, 18\] which may in part result from repression of E-cadherin expression \[19\]. More relevant to our work on the importance of the CAPERα/TBX3 complex to prevent senescence and regulate cell proliferation are studies reporting that Tbx3 improves the pluripotency of iPS cells \[20\] and prevents differentiation of mouse ES cells \[21\]. As of this writing, we have found no other studies directed at the role of TBX3 in repressing senescence in primary cells or *in vivo* and this is one of the important contributions of our manuscript. We have added this information to the Discussion section as requested by the reviewers.

Regarding lncRNAs in senescence, although there has been a logarithmic increase in studies exploring their expression and function, lncRNA regulation of senescence remains largely unexplored. LncRNA *HOTAIR* has been shown to function as a scaffold to regulate ubiquitination of Ataxin-1 and Snurportin-1 to prevent premature senescence \[22\]. Global alterations in lncRNA expression have been reported in association with replicative senescence and telomere specific lncRNAs that regulate telomere during this process have been identified function \[23, 24\]. We found no reports of lncRNAs sufficient to induce senescence.

We have added the above information to the Discussion as requested by the reviewers.
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